<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s12645-021-00081-z</query><apiKey>87ba7cb21f89ce78154df796840621f4</apiKey><result><total>1</total><start>1</start><pageLength>2</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="publisher-id">12645</journal-id><journal-id journal-id-type="doi">10.1007/12645.1868-6966</journal-id><journal-title-group><journal-title>Cancer Nanotechnology</journal-title><journal-subtitle>Basic,Translational and Clinical Research</journal-subtitle><abbrev-journal-title abbrev-type="publisher">Cancer Nano</abbrev-journal-title></journal-title-group><issn pub-type="ppub">1868-6958</issn><issn pub-type="epub">1868-6966</issn><publisher><publisher-name>Springer Vienna</publisher-name><publisher-loc>Vienna</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s12645-021-00081-z</article-id><article-id pub-id-type="manuscript">81</article-id><article-id pub-id-type="doi">10.1186/s12645-021-00081-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Development of Fe<sub>3</sub>O<sub>4</sub> core–TiO<sub>2</sub> shell nanocomposites and nanoconjugates as a foundation for neuroblastoma radiosensitization</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Liu</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Mirzoeva</surname><given-names>Salida</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Yuan</surname><given-names>Ye</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Deng</surname><given-names>Junjing</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Chen</surname><given-names>Si</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au6"><name><surname>Lai</surname><given-names>Barry</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au7"><name><surname>Vogt</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au8"><name><surname>Shah</surname><given-names>Karna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au9"><name><surname>Shroff</surname><given-names>Rahul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au10"><name><surname>Bleher</surname><given-names>Reiner</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au11"><name><surname>Jin</surname><given-names>Qiaoling</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au12"><name><surname>Vo</surname><given-names>Nghia</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" id="Au13"><name><surname>Bazak</surname><given-names>Remon</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" id="Au14"><name><surname>Ritner</surname><given-names>Carissa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au15"><name><surname>Gutionov</surname><given-names>Stanley</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au16"><name><surname>Raha</surname><given-names>Sumita</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au17"><name><surname>Sedlmair</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="Au18"><name><surname>Hirschmugl</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" id="Au19"><name><surname>Jacobsen</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au20"><name><surname>Paunesku</surname><given-names>Tatjana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au21"><name><surname>Kalapurkal</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au22"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9209-8954</contrib-id><name><surname>Woloschak</surname><given-names>Gayle E.</given-names></name><address><email>g-woloschak@northwestern.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1264502100081z_cor22">y</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.16753.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2299 3507</institution-id><institution content-type="org-division">Department of Radiation Oncology</institution><institution content-type="org-name">Northwestern University</institution></institution-wrap><addr-line content-type="postcode">60611</addr-line><addr-line content-type="city">Chicago</addr-line><addr-line content-type="state">IL</addr-line><country country="US">USA</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.16753.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2299 3507</institution-id><institution content-type="org-division">Department of Physics and Astronomy</institution><institution content-type="org-name">Northwestern University</institution></institution-wrap><addr-line content-type="postcode">60208</addr-line><addr-line content-type="city">Evanston</addr-line><addr-line content-type="state">IL</addr-line><country country="US">USA</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.187073.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 1939 4845</institution-id><institution content-type="org-division">X-Ray Science Division</institution><institution content-type="org-name">Argonne National Laboratory</institution></institution-wrap><addr-line content-type="postcode">60439</addr-line><addr-line content-type="city">Argonne</addr-line><addr-line content-type="state">IL</addr-line><country country="US">USA</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.16753.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2299 3507</institution-id><institution content-type="org-division">Chemistry of Life Processes Institute</institution><institution content-type="org-name">Northwestern University</institution></institution-wrap><addr-line content-type="postcode">60208</addr-line><addr-line content-type="city">Evanston</addr-line><addr-line content-type="state">IL</addr-line><country country="US">USA</country></aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.18785.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1764 0696</institution-id><institution content-type="org-name">Diamond Light Source Ltd, Harwell Science and Innovation Campus</institution></institution-wrap><addr-line content-type="postcode">OX11 0DE</addr-line><addr-line content-type="city">Didcot</addr-line><country country="GB">UK</country></aff><aff id="Aff6"><label>6</label><institution-wrap><institution content-type="org-name">Synchrotron Radiation Center</institution></institution-wrap><addr-line content-type="street">3731 Schneider Drive</addr-line><addr-line content-type="postcode">53589-3097</addr-line><addr-line content-type="city">Stoughton</addr-line><addr-line content-type="state">WI</addr-line><country country="US">USA</country></aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.267468.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0695 7223</institution-id><institution content-type="org-division">Physics Department</institution><institution content-type="org-name">University of Wisconsin-Milwaukee</institution></institution-wrap><addr-line content-type="postcode">53211</addr-line><addr-line content-type="city">Milwaukee</addr-line><addr-line content-type="state">WI</addr-line><country country="US">USA</country></aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.7155.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2260 6941</institution-id><institution content-type="org-division">Department of Otorhinolaryngology, Faculty of Medicine</institution><institution content-type="org-name">University of Alexandria</institution></institution-wrap><addr-line content-type="city">Alexandria</addr-line><country country="EG">Egypt</country></aff></contrib-group><author-notes><corresp id="IDs1264502100081z_cor22"><label>y</label><email>g-woloschak@northwestern.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>5</month><year>2021</year></pub-date><pub-date date-type="pub" publication-format="print"><month>12</month><year>2021</year></pub-date><volume>12</volume><issue seq="12">1</issue><elocation-id>12</elocation-id><history><date date-type="registration"><day>16</day><month>3</month><year>2021</year></date><date date-type="received"><day>26</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2021</year></date><date date-type="online"><day>14</day><month>5</month><year>2021</year></date></history><permissions><copyright-statement content-type="compact">© The Author(s) 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="uri">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract xml:lang="en" id="Abs1"><title>Abstract</title><sec id="ASec1"><title>Background</title><p id="Par1">Neuroblastoma is the most common extracranial solid malignancy in childhood which, despite the current progress in radiotherapy and chemotherapy protocols, still has a high mortality rate in high risk tumors. Nanomedicine offers exciting and unexploited opportunities to overcome the shortcomings of conventional medicine. The photocatalytic properties of Fe<sub>3</sub>O<sub>4</sub> core-TiO<sub>2</sub> shell nanocomposites and their potential for cell specific targeting suggest that nanoconstructs produced using Fe<sub>3</sub>O<sub>4</sub> core-TiO<sub>2</sub> shell nanocomposites could be used to enhance radiation effects in neuroblastoma. In this study, we evaluated bare, metaiodobenzylguanidine (MIBG) and 3,4-Dihydroxyphenylacetic acid (DOPAC) coated Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> as potential radiosensitizers for neuroblastoma in vitro.</p></sec><sec id="ASec2"><title>Results</title><p id="Par2">The uptake of bare and MIBG coated nanocomposites modestly sensitized neuroblastoma cells to ionizing radiation. Conversely, cells exposed to DOPAC coated nanocomposites exhibited a five-fold enhanced sensitivity to radiation, increased numbers of radiation induced DNA double-strand breaks, and apoptotic cell death. The addition of a peptide mimic of the epidermal growth factor (EGF) to nanoconjugates coated with MIBG altered their intracellular distribution. Cryo X-ray fluorescence microscopy tomography of frozen hydrated cells treated with these nanoconjugates revealed cytoplasmic as well as nuclear distribution of the nanoconstructs.</p></sec><sec id="ASec3"><title>Conclusions</title><p id="Par3">The intracellular distribution pattern of different nanoconjugates used in this study was different for different nanoconjugate surface molecules. Cells exposed to DOPAC covered nanoconjugates showed the smallest nanoconjugate uptake, with the most prominent pattern of large intracellular aggregates. Interestingly, cells treated with this nanoconjugate also showed the most pronounced radiosensitization effect in combination with the external beam x-ray irradiation. Further studies are necessary to evaluate mechanistic basis for this increased radiosensitization effect. Preliminary studies with the nanoparticles carrying an EGF mimicking peptide showed that this approach to targeting could perhaps be combined with a different approach to radiosensitization – use of nanoconjugates in combination with the radioactive iodine. Much additional work will be necessary in order to evaluate possible benefits of targeted nanoconjugates carrying radionuclides.</p></sec><sec id="ASec4" specific-use="web-only"><title>Graphic abstract</title><p specific-use="web-only"><fig id="Figa" position="anchor"><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12645_2021_81_Figa_HTML.png" position="anchor" id="MO1"/></fig></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nanocomposites</kwd><kwd>Nanoconjugates</kwd><kwd>Iron oxide core nanoparticles</kwd><kwd>Titanium dioxide shell nanoparticles</kwd><kwd>Neuroblastoma</kwd><kwd>Radiosensitization</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/100000057</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">GM104530</award-id><principal-award-recipient><name><surname>Jacobsen</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>National Cancer Institute</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/100000054</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">U54CA199091</award-id><award-id award-type="FundRef grant">CA107467</award-id><award-id award-type="FundRef grant">EB002100</award-id><principal-award-recipient><name><surname>Woloschak</surname><given-names>Gayle E.</given-names></name></principal-award-recipient><principal-award-recipient><name><surname>Woloschak</surname><given-names>Gayle E.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/100000002</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">SP0007167</award-id><principal-award-recipient><name><surname>Woloschak</surname><given-names>Gayle E.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>Make Your Mark Foundation</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>US DEPARTMENT of ENERGY</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">DE-AC02-06CH11357</award-id><award-id award-type="FundRef grant">LDRD 2013-168-N0</award-id><principal-award-recipient><name><surname>Jacobsen</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>Springer</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>12</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2021</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2021</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2021</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>16</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/12645_2021_Article_81.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Materials Science</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Nanotechnology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Cancer Research</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biomedical Engineering and Bioengineering</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biochemistry, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Chemistry and Materials Science</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="ESMHint"><title>Supplementary Information</title><p>The online version contains supplementary material available at <ext-link xlink:href="10.1186/s12645-021-00081-z" ext-link-type="doi">https://doi.org/10.1186/s12645-021-00081-z</ext-link>.</p></notes></front><body><sec id="Sec1"><title>Background</title><p id="Par29">Neuroblastoma is the most common extracranial solid malignancy among children under 15 years of age (Baade et al. <xref ref-type="bibr" rid="CR4">2010</xref>; Gatta et al. <xref ref-type="bibr" rid="CR26">2012</xref>; Kacar et al. <xref ref-type="bibr" rid="CR34">2013</xref>; Stiller <xref ref-type="bibr" rid="CR60">2004</xref>; Ward et al. <xref ref-type="bibr" rid="CR69">2014</xref>). It arises within the sympathetic nervous system from primordial neural crest cells of sympaticoadrenal lineage. Neuroblastoma is a heterogeneous tumor with a highly variable clinical behavior. Although low- to intermediate-risk tumors tend to have a favorable prognosis, high-risk tumors often exhibit less than 50% overall survival rate (Maris et al. <xref ref-type="bibr" rid="CR41">2007</xref>). The variable clinical outcome, which occasionally mounts to inexorable progression despite intensive therapy, reflects the genetic heterogeneity of these tumors (Aygun <xref ref-type="bibr" rid="CR3">2018</xref>). The most consistent genetic abnormality associated with adverse outcomes is genomic amplification of N-myc proto-oncogene (MYCN), which occurs in nearly 20% of primary tumors (Maris et al. <xref ref-type="bibr" rid="CR41">2007</xref>). Neuroblastoma is notorious for relapse, which occurs in up to 60% of cases and is often refractive to most currently available treatment modalities (Maris <xref ref-type="bibr" rid="CR40">2010</xref>). Primary neuroblastomas often have a wild-type p53 which in combination with MYCN, often results in treatment induced apoptosis (Yoshida <xref ref-type="bibr" rid="CR71">2018</xref>). However, upon relapse, neuroblastomas often become p53-negative which renders these tumors resistant to therapy (Huang and Weiss <xref ref-type="bibr" rid="CR32">2013</xref>). Gene sequencing of neuroblastoma samples has revealed that the genetic makeup of up to 78% of relapsed neuroblastomas harbors new genetic mutations in the RAS–mitogen-activated protein kinase pathway (RAS–MAPK) and novel MYCN amplifications (Eleveld et al. <xref ref-type="bibr" rid="CR23">2015</xref>; Schramm et al. <xref ref-type="bibr" rid="CR58">2015</xref>). The current standard of care for neuroblastoma entails multiple treatment modalities, all of which have a deleterious effect on health (Maris <xref ref-type="bibr" rid="CR40">2010</xref>). Even targeted therapies such as radioactive metaiodobenzylguanidine (MIBG) carry with it numerous treatment-related hurdles ranging from myelosuppression as the dose-limiting toxicity, to difficulties in isolating young radio-iodine treated children which is essential for protection of caregivers (DuBois and Matthay <xref ref-type="bibr" rid="CR21">2008</xref>; Matthay et al. <xref ref-type="bibr" rid="CR43">2012</xref>,<xref ref-type="bibr" rid="CR42">2007</xref>). New approaches with targeted therapies are under investigation; however, few are as efficient for relapsed neuroblastoma as treatment with radioactive MIBG. It should be noted that there are two types of radioactive iodine that can be used for preparation of MIBG. Typically, <sup>131</sup>I-MIBG is used for therapy, while <sup>123</sup>I-MIBG is used for diagnosis by scintigraphy (Nakatani et al. <xref ref-type="bibr" rid="CR48">2002</xref>). <sup>131</sup>I is a β-emitter, with an effective tissue penetration of 2 cm and it is most efficient when used for treatment of larger tumors where uptake by some of the cells kills the neighboring tumor cells (Cunningham et al. <xref ref-type="bibr" rid="CR17">1998</xref>). For micrometastases below 1 mm, the dose of <sup>131</sup>I-MIBG-derived radiation absorbed by the tumor vs. surrounding tissue declines significantly (Sisson et al. <xref ref-type="bibr" rid="CR59">1990</xref>). On the other hand, <sup>125</sup>I is a low-energy gamma emitter and an Auger electron emitter, with a maximum effective range of roughly 30 µm (Weber et al. <xref ref-type="bibr" rid="CR70">1996</xref>). Consequently, <sup>125</sup>I-MIBG is more effective in killing smaller metastases as shown in an animal model (Rutgers et al. <xref ref-type="bibr" rid="CR56">2000</xref>). Our work presented here is motivated by the possibility to use the short-range emitting <sup>125</sup>I-MIBG in combination with nanoparticles that may alter subcellular distribution of this agent and make it more potent. At the same time, we wished to explore whether the nanoparticles themselves had the capacity to increase sensitivity to radiation.</p><p id="Par30">Nanotechnology provides a myriad of encouraging targeting opportunities to tackle current limitations in conventional treatment modalities (Bazak et al. <xref ref-type="bibr" rid="CR6">2014</xref>,<xref ref-type="bibr" rid="CR7">2015</xref>). Fe<sub>3</sub>O<sub>4</sub> core–TiO<sub>2</sub> shell (Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>) nanocomposites are unique in having surface reactivity and photocatalytic properties that render them an attractive platform for inducing controlled targeted cytotoxicity and DNA scission in neoplastic cells (Bazak et al. <xref ref-type="bibr" rid="CR5">2013</xref>; Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>). The photocatalytic properties of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites are based on the ability of TiO<sub>2</sub> shell to produce reactive oxygen species (ROS) when exposed to photons with energies greater than 3.2 eV (Blake et al. <xref ref-type="bibr" rid="CR8">1999</xref>). These ROS interact with adjacent intracellular structures to induce direct deoxyribonucleic acid (DNA) damage (Cooke et al. <xref ref-type="bibr" rid="CR15">2003</xref>), mitochondrial ROS-induced ROS release (Zorov et al. <xref ref-type="bibr" rid="CR74">2006</xref>), and ultimately cell death (Ryter et al. <xref ref-type="bibr" rid="CR57">2007</xref>). Owing to the unique physico-chemical characteristics of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites, they have been explored in several contexts. Arora and others (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>) utilized Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconstructs for intracellular delivery of doxorubicin circumventing drug resistance in ovarian cancer cell lines. Bazak et al. (Bazak et al. <xref ref-type="bibr" rid="CR5">2013</xref>) and Yuan et al. (Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>) have targeted Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> to the nucleus of nasal and cervical cancer cell lines, and achieved light-induced genomic DNA degradation. Possible use of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> for active targeting coupled with controlled induction of cytotoxicity in neoplastic cells render these nanoconstructs a platform worth exploring for management of neuroblastoma. The possibility of using the nanoparticles targeted to cell nucleus is especially interesting when considering use of <sup>125</sup>I-MIBG-loaded nanoconstructs; as well as the possibility that the metal oxide component of the nanocomposite may increase radiation sensitivity in combination with external beam radiotherapy.</p><p id="Par31">In this study, we investigated whether bare and surface-modified Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites can enhance radiation-induced ROS production in four genetically distinct neuroblastoma cell lines. The SK-N-AS cell line has a mutated NRAS gene, a non-functional p53, and a single copy of MYCN. In contrast, SK-N-DZ cell line harbors a wild-type p53 (Nakamura et al. <xref ref-type="bibr" rid="CR47">2007</xref>), but with an amplified MYCN. Both NBL-W/S and NBL-W/N cell lines have about 100 copies of the MYCN gene (Foley et al. <xref ref-type="bibr" rid="CR25">1991</xref>); nevertheless, N-myc protein in NBL-W/S cells is tenfold less than in NBL-W/N due to differences in MYCN mRNA stability (Chagnovich and Cohn <xref ref-type="bibr" rid="CR11">1997</xref>). The cell lines used in this study are morphologically of the neuroblastic and substrate adherent phenotypes. Primary neuroblastoma is a heterogonous tumor and generally harbors cells of both phenotypes (Kim et al. <xref ref-type="bibr" rid="CR37">2004</xref>). We chose to work with a diverse set of neuroblastoma cell lines in order to observe relative differences in treatment efficiency of nanocomposites under investigation, reflecting the genetic and physiological diversity seen in the clinic. Some of the work, however, was conducted only on SK-N-AS cell line because these cells share many critical aspects of refractory neuroblastoma such as non-functional p53 and mutated NRAS gene (Eleveld et al. <xref ref-type="bibr" rid="CR23">2015</xref>).</p><p id="Par32">Neuroblastoma cell lines have been used as a model for investigation of dopamine uptake and synthesis (Cooke et al. <xref ref-type="bibr" rid="CR15">2003</xref>) and dopaminergic neuroblastoma has been associated with a poor clinical outcome (Nakagawara et al. <xref ref-type="bibr" rid="CR46">1988</xref>). Therefore, we explored 3,4-dihydroxyphenylacetic acid (DOPAC) as a possible coating for Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites. We have previously used dopamine and DOPAC to conjugate small molecules to nanocomposite surfaces (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>; Bazak et al. <xref ref-type="bibr" rid="CR5">2013</xref>; Brown et al. <xref ref-type="bibr" rid="CR9">2018</xref>; Chen et al. <xref ref-type="bibr" rid="CR12">2014</xref>; Paunesku et al. <xref ref-type="bibr" rid="CR53">2003</xref>,<xref ref-type="bibr" rid="CR54">2007</xref>; Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>); however, in this study DOPAC itself was designated to serve as nanocomposite surface modification as well as anchor for conjugation of MIBG.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Modification of nanocomposite surface coating affects size, aggregation, and cellular uptake</title><p id="Par33">We examined how the coating of nanocomposites with DOPAC or DOPAC conjugated to MIBG might affect nanoconjugate physical characteristics considering that the same nanocomposite colloid was used for preparation of the three final nanoconstructs. Measurements of zeta potentials of these nanoconstructs are shown in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Table S1. It should be noted that MIBG was conjugated to Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites via a DOPAC linker through a reaction using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and with MIBG as the molecule in higher excess. Under these conditions, no free COOH groups of DOPAC remained on the nanoconjugate surface. We refer to those nanoconjugates as MIBG-coated although it is DOPAC that provides a covalent link between nanoconstruct surface and MIBG (see Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figures S1 and S2). These nanocomposites were imaged by energy dispersive spectroscopy (EDS)–scanning transmission electron microscopy (STEM) (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1), and elemental maps were generated. There was a clear overlap between iodine (I), iron (Fe), and titanium (Ti) in the elemental map images seen in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1b, indicating the successful binding of MIBG to the surface of the nanocomposite. Progression through chemical changes on the surface of the nanocomposites correlated with nanoparticle coating was also confirmed by infrared spectroscopy (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S2).</p><p id="Par34">Bare, DOPAC and MIBG-coated nanoconjugates were produced from the same initial nanocomposites, cleaned by dialysis and suspended in serum-containing cell growth medium. Nanoconjugate suspensions were drop cast onto lacey-carbon grids for transmission electron microscopy (TEM), plunge-frozen, and imaged under cryogenic conditions (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a–c). We observed a difference in size and aggregation properties of the different nanoconstructs under these conditions. In complete medium, aggregates formed from bare nanocomposites were much smaller than aggregates of DOPAC-coated nanoconjugates. MIBG-coated nanoconjugates were similar in size and aggregation to the bare nanocomposites. It is possible that the highly polar surface of DOPAC-coated nanoconjugates, with numerous electronegative carboxyl groups exposed to the medium, led to cooperative binding to electropositive components in the complete medium and aggregation of nanoconjugates, while bare and MIBG-coated nanoconstructs acquired only a single layer of protein corona.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>Nanocomposite and nanoconjugate Cryo-TEM show different degrees of aggregation resulting in corresponding differences in nanocomposite uptake by neuroblastoma cells. <bold>a</bold> Cryo-TEM images of bare Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites; <bold>b</bold> DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates, and <bold>c</bold> MIBG–DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates mixed with complete cell media, plunge-frozen on lacy carbon grids and imaged under cryogenic conditions at 120 kV. For EDS–STEM and IR spectroscopy of nanocomposites, see supplemental Figs. 1 and <xref rid="Fig2" ref-type="fig">2</xref>. <bold>d</bold> SK-N-AS cells were treated with 250 nM bare Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites, DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates or MIBG–DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates for 1 h (n = 3), washed and collected after trypsinization. Bar graph shows relative quantity of Ti per 10<sup>5</sup> cells; <bold>e</bold> same work was done with SK-N-DZ cells. The total concentration of Ti (ppb) per sample was evaluated by ICP-MS and adjusted for the number of cells counted prior to sample processing for ICP-MS. The final concentration of Ti per 10<sup>5</sup> cells is expressed as a percentage of bare Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposite uptake; control value corresponds to Ti background from cells not treated with nanoconstructs. Data presented are an average of at least two independent experiments, each with three biological replicates. Error bars indicate mean ± SD. *** &lt; 0.001 significance level</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12645_2021_81_Fig1_HTML.png" id="MO2"/></fig></p><p id="Par35">We examined cellular uptake of bare, DOPAC- and MIBG-coated nanoconstructs by inductively coupled plasma-mass spectrometry (ICP-MS) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>d, e). When neuroblastoma cells (SK-N-AS and SK-N-DZ) were treated for 1 h with equivalent concentrations of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites (250 nM), there was significantly less uptake of DOPAC-coated nanoconjugates when compared to either bare nanocomposites or MIBG-coated nanoconjugates in both cell lines. This could be explained by the observed difference in aggregation properties of the nanoconstructs. The observed size of bare and MIBG-coated nanoparticles aggregates imaged by TEM was much smaller compared to aggregates of DOPAC-coated nanoconjugates.</p></sec><sec id="Sec4"><title>Modification of nanocomposite surface coating modulates subcellular localization of nanoconstructs</title><p id="Par36">Using Cryo-X-ray fluorescence microscopy (Cryo-XFM), we examined whether bare, DOPAC- and MIBG-coated nanoconstructs are transported to different subcellular locations after uptake. XFM provides complete elemental spectra for each pixel of the raster-scanned sample and elemental distribution of biologically ubiquitous elements permits identification of cells and subcellular organelles. In figures of XFM maps, sulfur (S) outlines the area of the whole cells because S is a common element in all cellular proteins due to the presence of methionine and cysteine amino acids (Ortega et al. <xref ref-type="bibr" rid="CR49">2004</xref>). Zinc (Zn) is present throughout the cell as well, but it is especially abundant in the nucleus (Finney et al. <xref ref-type="bibr" rid="CR24">2007</xref>; Glesne et al. <xref ref-type="bibr" rid="CR28">2006</xref>; Paunesku et al. <xref ref-type="bibr" rid="CR53">2003</xref>) , while the presence of manganese (Mn) indicates locations of mitochondria primarily because of the concentrated presence of manganese superoxide dismutase (MnSOD) (Paunesku et al. <xref ref-type="bibr" rid="CR53">2003</xref>,<xref ref-type="bibr" rid="CR54">2007</xref>). Iodine (I) background in cells is extremely low; this permitted us to use I as a proxy for MIBG distribution; cells left untreated or treated with nanoconjugates without MIBG only showed background I signal. 10-keV incident X-rays excited fluorescence of L shell electrons of I, while all other elements included in Fig. <xref rid="Fig2" ref-type="fig">2</xref> were identified through their K shell fluorescence signals. There is no titanium (Ti) in the cells and the presence of Ti signal indicates location of nanoparticle aggregates (Paunesku et al. <xref ref-type="bibr" rid="CR53">2003</xref>,<xref ref-type="bibr" rid="CR54">2007</xref>). Especially, co-localization of characteristic K alpha electron shell signals of Ti and Fe indicates the position of the metal oxide component of nanoconjugates–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites themselves. XFM allows quantitative, tomographic, elemental mapping of whole, non-sectioned cells and therefore enables precise measurement and mapping of nanocomposite/nanoconjugate distribution in cells. Moreover, since X-ray fluorescence is an inherent elemental property, this mode of imaging allows for detection of nanoconjugates/nanocomposites without necessitating the addition of dyes to the particle for detection, which could significantly alter the functional properties of that nanoparticle (Grätzel <xref ref-type="bibr" rid="CR30">2004</xref>; Rajh et al. <xref ref-type="bibr" rid="CR55">2002</xref>). In addition, images obtained with cryogenic XFM technique show elemental content of the cells without elemental re-distribution that can be caused by fixation or drying. Using Cryo-XFM, we observed that bare nanocomposites (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a) as indicated by Ti and Fe show a punctate cytoplasmic distribution pattern in SK-N-AS cells. Because one of the nanoparticle aggregates (yellow arrowheads in Fig. <xref rid="Fig2" ref-type="fig">2</xref>a) appeared as overlapping with the Zn-high region corresponding to cell nucleus, we have re-imaged this area of the sample after a 45 degree rotation which gave us a different vantage point. This XFM scan showed separation between the cell nucleus and nanocomposite aggregates (yellow arrowheads in Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). In Fig. <xref rid="Fig2" ref-type="fig">2</xref>c, d, we examined the pattern of distribution of DOPAC-coated nanocomposites in AS cells. Two distinct modes of distribution were observed for cells treated with DOPAC-nanoconjugates. The first, presented in Fig. <xref rid="Fig2" ref-type="fig">2</xref>c, was a large aggregation of nanocomposites while the second, in Fig. <xref rid="Fig2" ref-type="fig">2</xref>d, was a punctate distribution of smaller nanocomposite aggregates in addition to a large aggregate associated with its perimeter. Cells treated with MIBG-coated nanoconjugates showed only a punctate distribution pattern for Ti and Fe (Fig. <xref rid="Fig2" ref-type="fig">2</xref>e–g); these small puncta were associated with I signal as well. Interestingly, several MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> aggregates co-localized with Mn, a marker for mitochondria. In order to investigate this from an additional vantage point, we re-scanned areas containing nanoconjugate puncta after ± 60-degree rotations. Elemental co-localization between Ti and Mn was still observed for several of the aggregates (Fig. <xref rid="Fig2" ref-type="fig">2</xref>f); at the same time, an apparently nucleus-associated aggregate nc1 was localized in the perinuclear region, rather than within the nucleus itself (Fig. <xref rid="Fig2" ref-type="fig">2</xref>g).<fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><p>Cryo-XFM imaging of SK-N-AS cells treated with three different nanocomposites. <bold>a</bold> SK-N-AS cells were treated with 250 nM Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites for 1 h. The distribution of Ti and Fe (as proxy for nanocomposites) in SK-N-AS cells was cytoplasmic or associated with the membrane; <bold>b</bold> the same cell was imaged after a 45 degree rotation, with all Ti signal separated from the Zn-rich area of the nucleus; <bold>c</bold> SK-N-AS cells treated with DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates showing large aggregates with dense concentration of Ti and Fe; <bold>d</bold> SK-N-AS cells also display punctate pattern of smaller aggregates of nanocomposites apparently co-localizing with Mn and Zn signal. <bold>e</bold> SK-N-AS cells treated with MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates. Some co-localization of Ti and Fe puncta with Mn and Zn is observed, indicating either potential mitochondrial or nuclear distribution of MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates. <bold>f</bold> After a + 60 degree rotation, image of the lower portion of same cell is still indicating Ti and Mn co-localization for aggregates nc 3 and nc 4; <bold>g</bold> scan of the upper portion of the same cell after a -60 degree rotation suggests that aggregate nc1 is in fact immediately above the nucleus. Scale bar and elemental concentration indicator (black—no signal to red—highest signal) are located under each image</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12645_2021_81_Fig2_HTML.png" id="MO3"/></fig></p><p id="Par37">Previous reports showed that distribution of MIBG molecule is cytoplasmic and mitochondrial in neuroblastoma cells (Gaze et al. <xref ref-type="bibr" rid="CR27">1991</xref>). The study that established this finding implemented electron spectroscopic imaging of thin sectioned cells. However, elemental sensitivity in this work was limited and some have even hypothesized that MIBG diffusion throughout the cell and its presence in specific subcellular compartments may be an artifact of fixation (Clerc et al. <xref ref-type="bibr" rid="CR13">1993</xref>). In an effort to prevent MIBG redistribution and obtain information about cells that were not sectioned, we used Cryo-XFM to image iodine distribution in MIBG treated whole frozen hydrated cells. Cryogenic conditions were found to preserve cellular architecture as well as the distribution of small molecules in cultured cells, unlike chemical fixation (Chen et al. <xref ref-type="bibr" rid="CR12">2014</xref>).</p><p id="Par38">SK-N-AS and SK-N-DZ cells were grown on silica nitride windows, treated with MIBG, frozen and imaged by Cryo-XFM (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S3a–c). Iodine was distributed through the cytoplasm and perinuclear areas, with very little iodine signal overlapping with the nucleus (Zn rich area). Contrary to previous studies, we demonstrated that MIBG is not localized only to the mitochondria. This finding is confirmed by high-resolution scans of the mitochondria in SK-N-AS (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S3c) and SK-N-DZ (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S3d) cells. Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S3e presents a table of the average iodine concentration ratios in the cytoplasm vs. nucleus and the mitochondria vs. cytoplasm. It is important to note that whole-cell XFM imaging without tomographic mapping has to be interpreted with care. For example, the iodine in the cytoplasmic layer directly above the nucleus could be erroneously interpreted as nucleus-associated signal when whole-cell imaging is performed only in 2D. Similar patterns of MIBG distribution were observed in cells treated with lower concentrations of this molecule (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S4).</p><p id="Par39">Neither free MIBG nor MIBG-coated nanoconjugates were observed in neuroblastoma cell nuclei as shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S3. One motivation for this work was to develop an approach to deliver MIBG into cell nucleus, with the view to enable delivery of <sup>125</sup>I immediately adjacent to the genomic DNA. In an effort to determine if it is ever possible for MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites to reach the nucleus, we have added onto nanocomposite surface a targeting moiety - an EGF-mimicking “B-loop” peptide (Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>). We have previously shown that Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites conjugated to this peptide bind to epidermal growth factor receptor (EGFR) and utilize the EGFR cellular trafficking to localize partially to the cell nucleus of HeLa cells (Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>). MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>–EGFB-loop nanoconjugates were used to treat cells grown on silica nitride windows, at a concentration equivalent to 60 µM MIBG and 637 nM nanocomposites. Treatment lasted for 90 min in serum-free medium at 37 °C; windows were washed, plunge-frozen in liquid ethane and imaged with the Bionanoprobe X-ray fluorescence imaging instrument at APS. In Fig. <xref rid="Fig3" ref-type="fig">3</xref>a, elemental maps of an SK-N-AS cell treated with MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>-B-loop nanoconjugates are presented. The nanoconjugates were detected within the nucleus, although the majority of nanoconjugates remained in the cytoplasm. To confirm this finding, a full tomographic dataset of 2D maps covering a total rotation over 138 degrees was obtained. Image reconstruction and visualization at a variety of angles are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>b–e and Additional file <xref ref-type="supplementary-material" rid="MOESM2">2</xref>: Video. Tomography confirmed nuclear localization of MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>-B-loop nanoconjugates as indicated by the presence of Ti, Fe as well as I. Elemental quantification of Ti in a region of interest drawn for the nucleus accounted for 35.3% of complete Ti inside the cell, similar to our findings with nanocomposites coated with B-loop in the HeLa cell line (Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>). The trafficking of EGFR to the nucleus is partial (Dittmann et al. <xref ref-type="bibr" rid="CR20">2010</xref>; Dittmann et al. <xref ref-type="bibr" rid="CR19">2008</xref>; Lin et al. <xref ref-type="bibr" rid="CR38">2001</xref> 11533659; Lo et al. <xref ref-type="bibr" rid="CR39">2006</xref>; Wang et al. <xref ref-type="bibr" rid="CR68">2010</xref>; Wang et al. <xref ref-type="bibr" rid="CR68">2010</xref>) and only a portion of the targeted nanoconjugates can be expected to reach the nucleus. Figure <xref rid="Fig3" ref-type="fig">3</xref>f presents image of an SK-N-DZ cell from the cell sample treated with MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>-B-loop nanoconjugates at the same concentration as the SK-M-AS cell line. A full tomographic dataset for this cell was not obtained due to time constraints for tomographic XFM imaging; however, a strong overlap between the Zn signal (nucleus) and Ti signal (nanoconjugate) suggests that the nanoconjugate aggregate is spatially associated with the nucleus. Although it has been suggested that nuclear pores uptake can accommodate structures from 39 to 234 nm (Misra and Sahoo <xref ref-type="bibr" rid="CR45">2010</xref>; Pante and Kann <xref ref-type="bibr" rid="CR51">2002</xref>; Paulo et al. <xref ref-type="bibr" rid="CR52">2011</xref>), larger aggregates that cannot completely translocate into the nucleus may nevertheless remain lodged in the nuclear membrane.<fig id="Fig3"><label>Fig. 3</label><caption xml:lang="en"><p>Tomographic imaging of targeted MIBG–Fe3O4@TiO2–B-loop nanoconjugates by Cryo-XFM indicates partial nuclear localization of the nanoconjugates. <bold>a</bold> A single XFM projection of a SK-N-AS cell treated with a 60 µM equivalent treatment of MIBG–Fe3O4@TiO2–B-loop nanoconjugates indicates extensive cytoplasmic and nuclear accumulation of nanoconjugates. Scale bar and elemental concentration indicator (black—no signal to red—highest signal) are located under image. Co-localization image: blue: iodine, red: Ti, green: zinc (overlapping color for all three elements is white). <bold>b</bold>–<bold>d </bold>Screen captures of different single-angle projections of the tomographic reconstruction of the cell seen in <bold>a</bold>. Different rotation projections confirm the localization of Ti and Fe in the nucleus. <bold>e</bold> Rotation projection focused on the iodine signal (indication of MIBG) corresponds to the same locations in the cell nucleus seen in <bold>b</bold>. <bold>f</bold> SK-N-DZ cell treated with MIBG–Fe3O4@TiO2–B-loop nanoconjugates, also suggesting nuclear localization of I and Ti</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12645_2021_81_Fig3_HTML.png" id="MO4"/></fig></p></sec><sec id="Sec5"><title>Nanoconjugate surface coating influences cell viability in nanoconjugate-treated neuroblastoma cells</title><p id="Par40">Because cell treatments with metal oxide nanoparticles in general are never free of side-effects, we wished to see whether such effects could be used to additional determent of cancer cells. We examined the effect of nanoconjugates on viability of neuroblastoma cell lines. Treatment with bare Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites at concentrations up to 250 nM did not significantly affect viability of either SK-N-AS (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S5a), SK-N-DZ (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S5b) or NBL-W/S (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S5c) cell lines measured by MTS assay 72 h after nanoconstructs treatment. However, viability of NBL-W/N cells (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S5d) treated with 250 nM bare nanocomposites was reduced to nearly 50%. MIBG molecule concentrations of up to 30 μM had minimal effect on viability of SK-N-AS and SK-N-DZ cells (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S5e, f).</p><p id="Par41">Interestingly, all four cell types have shown a statistically significant decrease in viability when treated with MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a–d). Maximal nanocomposite concentration tested was 250 nM while corresponding maximal concentration of MIBG was 23.59 μM. Viability of SK-N-AS and NBL-W/S cells was affected only at the 250 nM concentration of MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates, while the loss of viability of SK-N-DZ cells was significant starting at 50 nM MIBG nanoconjugate concentration and at 100 nM concentration in cell line NBL-W/N. We also investigated if this effect on cell viability was notable only in neuroblastoma cells by investigating MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugate effect on a non-neuroblastoma cell line, HeLa (Fig. <xref rid="Fig4" ref-type="fig">4</xref>e). These cells do not express a norepinephrine receptor critical for MIBG-specific uptake (Glowniak et al. <xref ref-type="bibr" rid="CR29">1993</xref>). We found that there was no significant difference in cytotoxicity between HeLa cells treated with bare nanocomposites or MIBG nanoconjugates. Finally, we examined if the effect of MIBG nanoconjugates on cytotoxicity could be explained by a process whereby free MIBG could induce additional nanocomposite uptake or another cellular response, leading to the observed significant effect on cytotoxicity. When a co-treatment of the most responsive of the four cell lines SK-N-DZ cells was done with simultaneous addition of bare nanocomposites (100 nM) and free MIBG (in concentration of 9.3 μM, equivalent to what was present on 100 nM MIBG-coated nanoconjugates concentration), no significant decrease in viability was observed (Fig. <xref rid="Fig4" ref-type="fig">4</xref>f).<fig id="Fig4"><label>Fig. 4</label><caption xml:lang="en"><p>Effect of MIBG nanoconjugates on neuroblastoma cell viability. <bold>a</bold> SK-N-AS cells; <bold>b</bold> SK-N-DZ; <bold>c</bold> NBL-W/S and <bold>d</bold> NBL-W/N were treated with varying concentrations of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>–MIBG nanoconjugates. Loss of viability was observed by MTS assay as detailed. <bold>e</bold> HeLa cells treated with 100 nM or 250 nM Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> bare nanocomposites or MIBG nanoconjugates. <bold>f</bold> SK-N-DZ cells treated with free MIBG (9.3 µM), bare nanocomposites (100 nM), or bare nanocomposites + free MIBG. No decrease in cell viability was found in either treatment condition *: &lt; 0.05 significance level, **: &lt; 0.01 significance level, *** &lt; 0.001 significance level. Datapoints presented are an average of 5 biological replicates. Error bars indicate mean ± SD</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12645_2021_81_Fig4_HTML.png" id="MO5"/></fig></p></sec><sec id="Sec6"><title>Decrease of cell viability caused by ionizing radiation is enhanced in the presence of DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates</title><p id="Par42">Neuroblastoma cell lines used in this study differed significantly with respect to radiation sensitivity (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S6), with cell line SK-N-AS being the most radiation resistant. We evaluated the use of bare nanocomposites, free DOPAC and DOPAC-coated Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates as possible radiation sensitizers (Fig. <xref rid="Fig5" ref-type="fig">5</xref>, Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S7). Typically, a sensitizer enhancement ratio (SER) is calculated as the ratio of the dose necessary to achieve a particular level of cell killing in the absence of the sensitizer and in the presence of the sensitizer (Tubiana <xref ref-type="bibr" rid="CR64">2005</xref>). In this case, we define the nanocomposite radiation enhancement ratio (NRER) to be the ratio of the percentage of cell viability at a particular radiation dose in the absence of nanocomposites to the percentage of viability in the presence of nanocomposites. An overview of cell viability is presented in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>. Significant enhancement of radiation effects was observed in SK-N-AS cells for exposures to 2, 5, and 10 Gy in the presence of 250 nM bare nanocomposites. In SK-N-DZ cells, significant enhancement was observed at 5 and 10 Gy in the presence of 250 nM bare nanocomposites. The calculated NRER for bare nanocomposites at 10 Gy was 1.2 for SK-N-AS cells and 1.24 for SK-N-DZ cells.<fig id="Fig5"><label>Fig. 5</label><caption xml:lang="en"><p>Radiosensitizing effects of bare nanocomposites and DOPAC-coated nanoconjugates. <bold>a</bold>, <bold>c</bold> SK-N-AS and <bold>b</bold>, <bold>d</bold> SK-N-DZ cells were irradiated in the presence of bare (Bare-NCs) or DOPAC-coated (DOPAC-NCs) nanoconstructs of different concentrations. Curves were generated by adjusting cell viabilities to 100% for non-irradiated cells in each nanoconstruct treated group. A statistically significant radiosensitizing effect was observed at 250 nM bare nanocomposites in both cell lines, particularly at 10 Gy. Datapoints presented are average of 5 biological replicates and are representative of at least two independent MTS experiments. Error bars indicate mean ± SD. <bold>e</bold> Annexin V/propidium iodide flow cytometry assay of SK-N-AS cells 24 h after irradiation (0 or 10 Gy) preceded by treatment with 250 nM DOPAC-nanocomposites. H<sub>2</sub>O<sub>2</sub> was the positive control. Three independent experiments were done, with 3 biological replicates per experiment. Con = cells not exposed to nanoconjugates; NC = DOPAC nanoconjugate treatment; <bold>f</bold> percentage of SK-N-AS cells with &gt; 20 foci per nucleus, for untreated or treated with 250 nM bare nanocomposites or 250 nM DOPAC-nanoconjugates for one hour and irradiated as indicated. 53BP1 foci were stained by immunocytochemistry while the nuclei were counterstained with propidium iodide (PI). At least 100 cells were counted for each treatment group per replicate. N = total number of biological replicates from 4 independent experiments of 1–2 replicates each. There was a significant increase in the percentage of cells with &gt; 20 foci after 2 Gy treatment. <bold>g</bold> Representative images of cells shown in <bold>f</bold>. Error bars indicate mean ± SD. * &lt; 0.05 significance level, ** &lt; 0.01 significance level, *** &lt; 0.001 significance level when treatment sample is compared to untreated and/or unirradiated control</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12645_2021_81_Fig5_HTML.png" id="MO6"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Cell viabilities in the presence of bare nanocomposites following irradiation</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2"><p>Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub></p></td><td align="left"><p>0 nM</p></td><td char="±" align="char"><p>100 nM</p></td><td char="±" align="char"><p>250 nM</p></td></tr><tr><td align="left" rowspan="4"><p>SK-N-AS</p></td><td align="left"><p>0 Gy</p></td><td align="left"><p>100 ± 2.22</p></td><td char="±" align="char"><p>100 ± 2.00</p></td><td char="±" align="char"><p>100 ± 1.42</p></td></tr><tr><td align="left"><p>2 Gy</p></td><td align="left"><p>88.15 ± 2.85</p></td><td char="±" align="char"><p>88.10 ± 3.60</p></td><td char="±" align="char"><p>82.22 ± 2.50**</p></td></tr><tr><td align="left"><p>5 Gy</p></td><td align="left"><p>60.00 ± 1.63</p></td><td char="±" align="char"><p>59.61 ± 1.73</p></td><td char="±" align="char"><p>50.30 ± 4.49**</p></td></tr><tr><td align="left"><p>10 Gy</p></td><td align="left"><p>38.90 ± 3.16</p></td><td char="±" align="char"><p>38.40 ± 4.53</p></td><td char="±" align="char"><p>32.35 ± 2.49**</p></td></tr><tr><td align="left" rowspan="4"><p>SK-N-DZ</p></td><td align="left"><p>0 Gy</p></td><td align="left"><p>100 ± 7.42</p></td><td char="±" align="char"><p>100 ± 9.29</p></td><td char="±" align="char"><p>100 ± 1.86</p></td></tr><tr><td align="left"><p>2 Gy</p></td><td align="left"><p>78.68 ± 2.70</p></td><td char="±" align="char"><p>77.00 ± 3.18</p></td><td char="±" align="char"><p>74.55 ± 3.18</p></td></tr><tr><td align="left"><p>5 Gy</p></td><td align="left"><p>52.13 ± 2.46</p></td><td char="±" align="char"><p>51.35 ± 2.47</p></td><td char="±" align="char"><p>46.89 ± 1.64**</p></td></tr><tr><td align="left"><p>10 Gy</p></td><td align="left"><p>31.14 ± 2.78</p></td><td char="±" align="char"><p>29.01 ± 3.53</p></td><td char="±" align="char"><p>25.03 ± 2.05**</p></td></tr></tbody></table><table-wrap-foot><p>Table of cell viabilities (expressed as % of non-irradiated treatment control for a given concentration of nanoconjugates, after adjustment for baseline cytotoxicity) for SK-N-AS and SK-N-DZ cells treated with varying concentrations of bare nanocomposites and different doses of ionizing radiation (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Entries contain mean ± SD. **: &lt; 0.01 significance level, *** &lt; 0.001 significance level.</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>Cell viabilities in the presence of DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates following irradiation</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2"><p>DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub></p></td><td char="±" align="char"><p>0 nM</p></td><td char="±" align="char"><p>100 nM</p></td><td char="±" align="char"><p>250 nM</p></td></tr><tr><td align="left" rowspan="4"><p>SK-N-AS</p></td><td align="left"><p>0 Gy</p></td><td char="±" align="char"><p>100 ± 5.06</p></td><td char="±" align="char"><p>100 ± 4.50</p></td><td char="±" align="char"><p>100 ± 10.11</p></td></tr><tr><td align="left"><p>2 Gy</p></td><td char="±" align="char"><p>91.84 ± 5.50</p></td><td char="±" align="char"><p>57.60 ± 7.28***</p></td><td char="±" align="char"><p>53.50 ± 6.60***</p></td></tr><tr><td align="left"><p>5 Gy</p></td><td char="±" align="char"><p>59.38 ± 4.79</p></td><td char="±" align="char"><p>26.40 ± 5.56***</p></td><td char="±" align="char"><p>17.94 ± 4.54***</p></td></tr><tr><td align="left"><p>10 Gy</p></td><td char="±" align="char"><p>38.11 ± 2.35</p></td><td char="±" align="char"><p>14.53 ± 3.50***</p></td><td char="±" align="char"><p>7.58 ± 5.67***</p></td></tr><tr><td align="left" rowspan="4"><p>SK-N-DZ</p></td><td align="left"><p>0 Gy</p></td><td char="±" align="char"><p>100 ± 10.12</p></td><td char="±" align="char"><p>100 ± 9.28</p></td><td char="±" align="char"><p>100 ± 17.87</p></td></tr><tr><td align="left"><p>2 Gy</p></td><td char="±" align="char"><p>51.97 ± 4.34</p></td><td char="±" align="char"><p>40.35 ± 10.15*</p></td><td char="±" align="char"><p>36.83 ± 17.71</p></td></tr><tr><td align="left"><p>5 Gy</p></td><td char="±" align="char"><p>40.06 ± 3.35</p></td><td char="±" align="char"><p>27.55 ± 3.86***</p></td><td char="±" align="char"><p>20.78 ± 12.76**</p></td></tr><tr><td align="left"><p>10 Gy</p></td><td char="±" align="char"><p>17.52 ± 3.23</p></td><td char="±" align="char"><p>8.25 ± 3.84**</p></td><td char="±" align="char"><p>5.20 ± 10.43*</p></td></tr></tbody></table><table-wrap-foot><p>Table of cell viabilities (expressed as % of non-irradiated treatment control for a given concentration of nanoconjugates, after adjustment for baseline cytotoxicity) for SK-N-AS and SK-N-DZ cells treated with varying concentrations of DOPAC-nanocomposites combined with varying doses of ionizing radiation, from Fig. <xref rid="Fig5" ref-type="fig">5</xref>. Entries contain mean ± SD. *: &lt; 0.05 significance level, **: &lt; 0.01 significance level, *** &lt; 0.001 significance level</p></table-wrap-foot></table-wrap></p><p id="Par43">As detailed above, we noted changes in uptake, subcellular localization, and size of aggregates of DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates compared to bare nanocomposites (Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). Neither bare nor DOPAC-covered nanoconjugates migrated to cell nucleus and we did not anticipate that they would show significantly different radiosensitization properties; nevertheless, NRER of DOPAC-covered nanoconjugates was markedly higher. In SK-N-AS and SK-N-DZ cells, significant radiation sensitization was observed at 2, 5, and 10 Gy (Table <xref rid="Tab2" ref-type="table">2</xref>) in combination with 100 and 250 nM nanoparticle concentrations. In this case, the NRER calculated for 250 nM DOPAC-nanoconjugates at 10 Gy was 5.03 and 3.37 for SK-N-AS and SK-N-DZ cells, respectively. To examine if this effect could be due to DOPAC alone, we repeated irradiations of neuroblastoma cells in the presence of DOPAC (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S7). Treatment of SK-N-AS and SK-N-DZ cells with concentrations of DOPAC equivalent to the DOPAC concentration bound to the nanocomposite surface (13 μM, 33 μM), or even at significantly higher concentrations (50 μM, 100 μM), had no additive or synergistic effect with irradiation in either cell line.</p><p id="Par44">We then examined the mode of cell death in SK-N-AS cells, the most radio-resistant cell line in this study (Fig. <xref rid="Fig5" ref-type="fig">5</xref>e). SK-N-AS cells were exposed to 10 Gy of ionizing radiation alone, 250 nM DOPAC-nanoconjugates alone, or a combination of the two. Cells were then incubated for 24 h, stained with Annexin-FITC and propidium iodide (PI), and evaluated by flow cytometry. Apoptosis was apparent in all treated samples. There was also a significant decrease in the number of live cells in samples treated with a combination of 10 Gy and DOPAC-nanoconjugates, compared to cells exposed either to 10 Gy alone or nanoconjugate alone. The percentage of live cells in 10 Gy and DOPAC-nanoconjugates treated cells was 70.43% at this time point, compared to 79.03% live cells after exposure to 10 Gy alone or 82.55% live cells after treatment with DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> alone. There was also a significant increase in early apoptotic cells in samples exposed to 10 Gy and DOPAC-nanoconjugates (12.26%) compared to untreated control (3.7%).</p><p id="Par45">Because intracellular distribution of DOPAC-nanoconjugates was cytoplasmic and the most likely physical product of interaction between the nanoparticles and ionizing radiation is the production or reactive oxygen species (ROS), we considered it questionable whether ROS produced by the nanoconjugates would reach genomic DNA to increase the damage caused to it by ionizing radiation. DNA damage is considered to be the most important effect of irradiation and the primary cause of radiation-induced cell death. To investigate the extent of double-stranded DNA breaks in the presence of DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates, we performed immunocytochemistry for p53-Binding Protein 1 (53BP1) foci, indicating sites of DNA double-strand breaks (Fig. <xref rid="Fig5" ref-type="fig">5</xref>f, g). SK-N-AS cells were treated with 2 Gy radiation alone, 250 nM bare nanocomposites alone, 250 nM DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates alone, or a combination of 2 Gy and either nanoconstruct. One hour after nanoconstruct treatment, cells were irradiated and allowed to recover in the incubator for 4 h. Then the cells were fixed and stained for 53BP1 foci and the nuclei were counterstained with propidium iodide (PI). Foci were counted for at least 100 cells per treatment group and the percentage of cells with 20 or more foci was determined. At 0 Gy, as expected, the cells with 20 or more foci were few. At 2 Gy there was a notable increase in the number of foci in all samples, but the greatest increase was seen in irradiated cells pretreated with DOPAC-nanoconjugates. These results indicate that the cellular uptake of DOPAC-nanocomposites leads to an increased accumulation of DNA double-strand breaks following irradiation with a dose as small as 2 Gy. It is worth noting that this dose of gamma irradiation did not significantly decrease the viability of either non-treated SK-N-AS cells or cells treated with bare nanocomposites (Table <xref rid="Tab1" ref-type="table">1</xref>, Fig. <xref rid="Fig4" ref-type="fig">4</xref>a). However, the same experiments have shown that a 2 Gy exposure of cells previously treated with 250 nM DOPAC-nanoconjugates has led to a 47% decrease in cell viability (Table <xref rid="Tab2" ref-type="table">2</xref>, Fig. <xref rid="Fig4" ref-type="fig">4</xref>c). Despite the correlation between the treatment with DOPAC-nanoconjugates, increase in DNA damage caused by ionizing radiation and increase in cell death, we cannot necessarily claim that accumulation of DNA damage or cell death were directly related to ROS production by DOPAC-nanoconjugates. Alternative explanations for these findings are possible, for example, perturbation of the cell membrane may lead to changes in signaling cascades that result in decreased DNA repair capacity. Our DNA damage evaluation was done at a late timepoint when much of the initial DNA damage in the cell may have already been repaired. Additional research will need to be done to establish the precise role of DOPAC-nanoconjugates in the increase of the genomic DNA damage accumulation after irradiation.</p></sec></sec><sec id="Sec7" sec-type="discussion"><title>Discussion</title><p id="Par46">Neuroblastoma is a highly lethal pediatric cancer where nearly 50% of patients present with metastasis at the time of diagnosis (DuBois et al. <xref ref-type="bibr" rid="CR22">1999</xref>; Maris et al. <xref ref-type="bibr" rid="CR41">2007</xref>). Recently, it has become evident that in patients who experience relapse, the recurrent tumor cells exhibit little resemblance to the original tumor genotype (Eleveld et al. <xref ref-type="bibr" rid="CR23">2015</xref>; Schramm et al. <xref ref-type="bibr" rid="CR58">2015</xref>). New mutations in genes associated with RAS–MAPK pathway accumulate in the course of disease development contributing to a poor prognosis (Eleveld et al. <xref ref-type="bibr" rid="CR23">2015</xref>; Schramm et al. <xref ref-type="bibr" rid="CR58">2015</xref>). Thus, many treatments that were initially successful become ineffective when relapse occurs (Huang and Weiss <xref ref-type="bibr" rid="CR32">2013</xref>). Management of relapse requires aggressive therapies including radionuclide treatments that are often limited because of associated toxicities. Several recent clinical studies used either high-dose or peptide-modified MIBG-based therapies (Kayano et al. <xref ref-type="bibr" rid="CR36">2020</xref>; Sugiyama et al. <xref ref-type="bibr" rid="CR61">2020</xref>). Despite some promising findings of these studies, development of more efficient treatments that work on most neuroblastoma phenotypes and for refractory disease is critically important. Few recent studies using different nanotechnology platforms to target neuroblastomas suggest that bionanotechnology is a promising direction for research in neuroblastoma (Alfei et al. <xref ref-type="bibr" rid="CR1">2020</xref>; Di Paolo et al. <xref ref-type="bibr" rid="CR18">2020</xref>).</p><p id="Par47">In an effort to exploit nanotechnology to enhance currently available treatment modalities, this study has examined a core–shell Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposite as a potential radiosensitizer in neuroblastoma cell lines. The effects of bare, MIBG and DOPAC-coated Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites alone or combined with radiation were evaluated in four neuroblastoma cell lines with dissimilar genetic makeup. In general, the cell line SK-N-AS showed the greatest resistance to radiation and both bare and DOPAC-coated Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates. In contrast, SK-N-DZ and NBL-W/N cell lines were sensitive to nanocomposites on their own as well as radiation alone. Combined use of radiation and nanocomposites led to more cell death than either treatment alone in SK-N-AS and SK-N-DZ cell lines. Interestingly, enhancement of radiation caused loss of cell viability due to the presence of nanoconstructs was similar in both cell lines.</p><p id="Par48">Exploiting the native cellular mechanisms of endocytosis and nuclear translocation of activated EGFR (Dittmann et al. <xref ref-type="bibr" rid="CR20">2010</xref>,<xref ref-type="bibr" rid="CR19">2008</xref>; Lin et al. <xref ref-type="bibr" rid="CR38">2001</xref>; Lo et al. <xref ref-type="bibr" rid="CR39">2006</xref>; Wang et al. <xref ref-type="bibr" rid="CR68">2010</xref>; Wang et al. <xref ref-type="bibr" rid="CR68">2010</xref>), we had previously used EGF-mimicking peptide to promote cellular uptake and nuclear translocation of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates (Yuan et al. <xref ref-type="bibr" rid="CR72">2013</xref>). Neuroblastomas widely express EGFR (Ho et al. <xref ref-type="bibr" rid="CR31">2005</xref>; Karmakar et al. <xref ref-type="bibr" rid="CR35">2009</xref>; Zage et al. <xref ref-type="bibr" rid="CR73">2013</xref>), and we used the same EGF-mimicking peptide to target nanoconstructs into nuclei of neuroblastoma cells as well. Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates without the EGFR-targeting peptide tend to accumulate in cytoplasm of SK-N-AS and SK-N-DZ neuroblastoma cells (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). We anticipated this as we have found cytoplasmic distribution of other non-targeted nanoparticles in other types of cell lines in the past (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>; Brown et al. <xref ref-type="bibr" rid="CR9">2018</xref>; Thurn et al. <xref ref-type="bibr" rid="CR63">2011</xref>,<xref ref-type="bibr" rid="CR62">2009</xref>). In contrast, XFM imaging has demonstrated that EGFR-targeting peptide promoted cellular and nuclear localization of these nanoconjugates (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). While EGFR targeting may deliver nanoconjugates to the cells and cell nuclei, other peptides such as G<sub>D2</sub> disialoganglioside could be used for targeting as well. G<sub>D2</sub> disialoganglioside is expressed on 98% of neuroblastoma cells, and it is already in use for antibody-based neuroblastoma therapies (Iavarone et al. <xref ref-type="bibr" rid="CR33">1993</xref>; Maris et al. <xref ref-type="bibr" rid="CR41">2007</xref>).</p><p id="Par49">MIBG has been shown to accumulate in nearly 85–90% of neuroblastoma through their expression of adrenaline/norepinephrine transporters (Carlin et al. <xref ref-type="bibr" rid="CR10">2003</xref>). Radioactive <sup>131</sup>I-MIBG is currently used for diagnosis (Paltiel et al. <xref ref-type="bibr" rid="CR50">1994</xref>) as well as the treatment of high-risk and refractory neuroblastoma (Kayano et al. <xref ref-type="bibr" rid="CR36">2020</xref>; Matthay et al. <xref ref-type="bibr" rid="CR42">2007</xref>; Sugiyama et al. <xref ref-type="bibr" rid="CR61">2020</xref>). In this study, we confirmed previous assessment that MIBG may accumulate in mitochondria (Gaze et al. <xref ref-type="bibr" rid="CR27">1991</xref>) as well as cytosol (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figures S3 and S4). MIBG-coated nanoconjugates did appear associated with the same cellular regions as well (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Nevertheless, radiosensitization of cells treated with MIBG nanoconjugates was less than 1.5-fold and further studies will be necessary to explore possible advantages of MIBG-coated nanoparticle preparation. One of the ideas that inspired us to add EGFR-targeting peptide to the MIBG-coated nanoconstructs was to evaluate whether this mode of MIBG delivery into cell nucleus may be successful. In our future work, we hope to explore effects of nucleus-targeted <sup>125</sup>I-MIBG-loaded nanoconstructs. This short-range emitter would produce less toxicity to normal tissues, and it could be expected to be efficient against micrometastases; in addition, its distribution in the patient could be evaluated by scintigraphy.</p></sec><sec id="Sec8" sec-type="conclusions"><title>Conclusions</title><p id="Par50">Our studies demonstrated that administration of bare and MIBG-coated Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites led to a modest increase in radiation toxicity in several neuroblastoma cell lines exposed to external beam radiation. On the other hand, DOPAC-coated nanocomposites despite aggregation and low cellular uptake dramatically increased sensitivity to radiation treatment in the neuroblastoma cells tested. Distribution of nanoconstructs and free MIBG in cells was studied by X-ray fluorescence microscopy. All non-targeted nanoconstructs accumulated, as expected, in cytoplasm, and occasionally, in the mitochondria. Nanocomposites targeted through the presence of the an EGF-mimicking peptide, on the other hand, partially entered the cell nuclei. An attractive potential future avenue of research would be to target radiolabeled-MIBG molecules into the cell nucleus using nucleus-targeted nanoconstructs. Such nanoconjugates could act as radiosensitizers for external beam therapy as well as deliver internal emitters close to the genomic DNA.</p></sec><sec id="Sec9" sec-type="methods"><title>Methods</title><sec id="Sec10"><title>Nanocomposite synthesis and characterization</title><p id="Par51">Fe<sub>3</sub>O<sub>4</sub> core and TiO<sub>2</sub> shell NPs (Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>) were synthesized through a modified low-temperature alkaline hydrolysis method as previously described (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>). Fe<sub>3</sub>O<sub>4</sub> nanoparticle cores were synthesized by stirring a solution of FeCl<sub>2</sub> and FeCl<sub>3</sub> in 24 mM citric acid for 3 h at room temperature. The mixture was then allowed to gel in static air at 70 °C for 24 h, forming the Fe<sub>3</sub>O<sub>4</sub> core nanoparticles 1.5 to 3 nm in size. This solution was chilled and stirred vigorously with the gradual addition of chilled TiCl<sub>4</sub> in HCl at 4 °C, allowing for the Ti shell to form. Elemental concentration determination of nanocomposite suspension was performed by measuring titanium and iron concentrations by ICP-MS at the Northwestern University Quantitative Bioelemental Imaging Center on an X series II ICP-MS (Thermo scientific, West Palm Beach, FL). The calculation used to determine the molarity of nanocomposites was previously described (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>), using atomic force microscopy (AFM) sizing calculations and elemental concentrations determined by ICP-MS.</p><p id="Par52">Following synthesis, Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites were dialyzed (dialysis tubing pore size = 2,000 MWCO) in 10 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 4.5) and stored at 4 °C. Under these conditions, phosphate molecules attach to the nanoparticle surface; this preparation constituted the “bare” nanocomposites (Michelmore et al. <xref ref-type="bibr" rid="CR44">2000</xref> ).</p><p id="Par53">MIBG (Sigma-Aldrich, St. Louis, MO) was bound with 3,4-dihydroxyphenylacetic acid (DOPAC) through a peptide bond-forming reaction using EDC (Thermo Scientific), following the manufacturer’s instructions. The final concentration of MIBG–DOPAC was 2.34 mM. DOPAC was used as a linker because it has a high affinity for the surface of nano-sized TiO<sub>2</sub> being a catechol with a carboxyl group that can form a peptide bond with the amino group of MIBG (Creutz and Chou <xref ref-type="bibr" rid="CR16">2008</xref>; Paunesku et al. <xref ref-type="bibr" rid="CR54">2007</xref>; Thurn et al. <xref ref-type="bibr" rid="CR62">2009</xref>). Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites were mixed overnight with DOPAC–MIBG in an oxygen-free atmosphere; the resultant nanoconjugates were dialyzed in 10 mM sodium phosphate buffer (dialysis pore size of 2,000 MWCO). Using a calculation approach previously described (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>), we estimated that mixing DOPAC–MIBG solution as prepared in equal volume with 22.3 μM Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites leads to DOPAC–MIBG covering roughly 70% of the nanoparticle surface.</p><p id="Par54">DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates were prepared by combining equal volumes of 7.838 mM DOPAC with 28.93 μM Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites in an oxygen-free environment followed by mixing the conjugation reaction overnight at 4 °C. DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites were then dialyzed for 2 h in 10 mM Na<sub>2</sub>HPO<sub>4</sub> buffer. We estimated that under these circumstances, molecules of DOPAC covered roughly 100% of the nanoparticle surface.</p><p id="Par55">Elemental makeup and the shape of Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>–MIBG nanoconjugates were evaluated by EDS–STEM, which was performed at the Northwestern University’s Atomic and Nanoscale Characterization Experimental Center (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1a–c). In preparation for EDS–STEM, Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>–MIBG nanoconjugates were diluted 1:100 in ddH<sub>2</sub>O, drop cast onto 150 square mesh copper grids with a carbon film support, allowed to dry, and then imaged on a Hitachi HD-2300 Dual EDS Cryo STEM (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1a).</p><p id="Par56">Infrared determination of nanocomposite coating (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S2) was performed using infrared spectroscopy at the infrared environmental imaging (IRENI) instrument at University of Wisconsin Synchrotron Center. Droplets of different nanoconjugate colloids or component solutions were cast and dried on Ultralene membrane supports and scanned in 2D. Chemograms for the areas of interest were obtained. The addition of each new nanoconjugate coating can be followed by appearance of new spectral features (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S2).</p><p id="Par57">Zeta-potential (ZP) measurements of the nanoconjugates were also obtained (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Table S1) using a protocol that was adapted from the procedure recommended by the Nanotechnology Characterization Laboratory at the National Cancer Institute (Clogston <xref ref-type="bibr" rid="CR14">2009</xref>). Bare nanocomposites, DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>, and MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates were diluted 1:100 in 10 mM filtered NaCl and ZP calculated using the following constants (temp: 25 °C, viscosity: 0.891, dielectric constant: 78.6, Henry function: 1.5, refractive index: 1.33) on a Zeta sizer Nano (Malvern, Worcestershire, United Kingdom). Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>–MIBG nanoconjugates have a mean ZP of -40.887 ± 1.85, bare (phosphate covered) Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates have a mean ZP of -37.1 ± 1.91, and DOPAC-coated nanocomposites have a mean ZP of -33.367 ± 0.71.</p><p id="Par58">Nanosight measurements were also performed using a Nanosight LM10-HS (Malvern, Worcestershire, United Kingdom) in lieu of dynamic light scattering (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Table S2). Because of the polydispersity of nanocomposites, presence of nanocomposite aggregates and the non-spherical shape of these objects, these results are not as reliable a source of nanoparticle size information as the AFM or TEM data.</p><p id="Par59">To further confirm the spatial and aggregation characteristics of different nanocomposites, Cryo-TEM (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a–c) was performed at the Northwestern University Biological Imaging Facility. Nanocomposite 1:100 dilutions in full media (DMEM + 10% FBS) of bare (phosphate coated) Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites, DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates, and MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates were drop cast on plasma-treated lacey carbon TEM grids, plunge-frozen in liquid ethane using a FEI Vitrobot Mark IV, and Cryo-TEM was performed using a JEOL 1230 TEM at 120 kV. Image brightness levels were adjusted to enhance contrast. The spatial and aggregation properties of different nanocomposites are similar, close to the value obtained by AFM and smaller than the size estimates obtained from the light scattering measurements done with the Nanosight instrument.</p><p id="Par60">EGFR B-loop peptide (DOPAC–MYIEALDKYAC-COOH) and scrambled peptide (DOPAC–EAKLDYMCIYA-COOH) were synthesized by the IBNAM (now The Simpson Querrey Institute for Bionanotechnology) Core Facility of Northwestern University’s Institute for Bionanotechnology in Medicine. The DOPAC group at the N-terminus of the peptide served as a linker to conjugate the peptide to the TiO<sub>2</sub> surface of the nanoparticles. B-loop peptide was dissolved to a concentration of 700 μM in ddH<sub>2</sub>O, bubbled with N<sub>2</sub>, then mixed in equal volume with 22.3 μM MIBG-nanocomposites or 28.93 μM bare nanocomposites. A separate set of nanocomposites was conjugated to a scrambled peptide. The conjugation was performed in an oxygen-free atmosphere overnight at 4 °C. At a concentration of 350 μM peptide and 11.15 μM MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>, it was estimated that the B-loop peptide should cover roughly 23% of the MIBG–nanoparticle surface, while with bare nanocomposites the surface coverage was estimated to be roughly 18% (Arora et al. <xref ref-type="bibr" rid="CR2">2012</xref>). Experiments with cells in culture were performed within 4 h following conjugation.</p></sec><sec id="Sec11"><title>Cell culture</title><p id="Par61">Neuroblastoma cell lines SK-N-AS and SK-N-DZ and cervical cancer cell line HeLa were purchased from American Type Culture Collection (ATCC, Manassas, Virginia). These cells were grown in DMEM supplemented with 10% non-heat inactivated FBS with penicillin/streptomycin and non-essential amino acids at 37 °C and 5% CO<sub>2</sub>. Neuroblastoma cell lines NBL-W/S and NBL-W/N were a generous gift from S.L. Cohn (Department of Pediatrics, University of Chicago, Chicago, IL). These cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated FBS with penicillin/streptomycin and L-glutamine.</p></sec><sec id="Sec12"><title>Cell viability assay</title><p id="Par62">SK-N-AS, SK-N-DZ, NBL-W/S, NBL-W/N, and HeLa cells were trypsinized, collected, counted, and plated (5–6 × 10<sup>3</sup> SK-N-AS cells per well, 6–7 × 10<sup>3</sup> SK-N-DZ, 9 × 10<sup>2</sup> NBL-W/S, 8–9 × 10<sup>3</sup> NBL-W/N, or 2.5 × 10<sup>3</sup> HeLa) into 96-well plates and allowed to attach overnight. Five to six wells for each cell line were used as biological replicates in each experiment. Cells were treated with varying concentrations of bare Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites, DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates, MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates, free DOPAC, free MIBG, DMSO (control for free MIBG experiments), or Na<sub>2</sub>HPO<sub>4</sub> buffer (10 mM, vehicle control for nanocomposites). In radiosensitization experiments, cells were treated with nanocomposites or nanoconjugates for 1 h, followed by varying doses of ionizing radiation. Cesium source (662 keV) Gamma Irradiator (Gammacell 40, Atomic Energy of Canada Ltd.) was used under the supervision of the Office of Research Safety, Health Physics Services, Northwestern University.</p><p id="Par63">Nanocomposite/nanoconjugate and irradiation treatments were performed in complete media over a period of 72 h. Equivalent “blank” wells without cells, but with an identical concentration of treatment reagents were used as blank controls (n = 5), in order to account for any possible modification of absorbance readout that could occur because of the treatment materials used. After incubation, a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS reagent, Promega, Madison WI) was added as 1/10th of the volume into each well, and the 96-well plates were incubated an additional 2–4 h at 37 °C. Initially, treatment media was removed from both treatment and blank wells before adding MTS and new media; this approach was discontinued when no significant differences in results were observed when MTS was added to wells without any prior manipulation. The latter approach was used subsequently in order to mitigate the risk of inadvertent removal of less adherent cells. Absorbance readings were measured using a SpectraMax M5 (Molecular Devices, Sunnyvale, CA) plate reader at 490 nm. Absorbance values measured for “blank” controls were averaged and subtracted from the treatment values. Resultant absorbance value was divided by the average of the absorbance values for each respective negative control, providing percentage of cell viability as a function of the control (surviving fraction). For radiation sensitization determination, each adjusted absorbance value was divided by the average of each treatment group respective baseline (cells treated with nanocomposites or nanoconjugates but not exposed to radiation) absorbance, to obtain an adjusted percentage of survival, to account for baseline cell death.</p></sec><sec id="Sec13"><title>Evaluation of nanocomposite and nanoconjugate uptake by ICP-MS</title><p id="Par64">SK-N-AS and SK-N-DZ cells were trypsinized, counted, and plated (5–8 × 10<sup>5</sup> of SK-N-AS cells, or 6–10 × 10<sup>5</sup> SK-N-DZ cells) onto 6-well plates and allowed to attach overnight. Empty wells with identical treatment conditions were also prepared, to act as a control for potential artifacts such as adherence of nanocomposites to the bottom of the wells in absence of cells. Additional wells seeded with an identical number of SK-N-AS or SK-N-DZ cells were used to estimate the final number of cells per well at the conclusion of experiment and to determine background elemental concentrations. Treatments with 250 nM bare Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites, 250 nM DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites, or 250 nM MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates were done in compete media (total volume of media per well was 1 ml) for 1 h at 37 °C; three wells per treatment represented biological replicates. After treatment, the wells were washed 1–3 times with PBS and once with acidic glycine. Finally, 500 μL of 70% HNO<sub>3</sub> (re-distilled, &gt; 99.999% trace metal basis) was added per well and cells and nanoconjugates were digested for 2 h at room temperature. Samples were then transferred into 15-ml metal-free Falcon tubes, mixed with 10 mL 3% HNO<sub>3</sub> in ddH<sub>2</sub>O containing 3 ppb <sup>115</sup>In (as an internal control), and allowed to digest additionally overnight at 70 °C. Samples were evaluated for elemental concentrations of <sup>47</sup>Ti, <sup>57</sup>Fe, and <sup>115</sup>In using an X series II ICP-MS. Ti concentration was used as a proxy for nanoparticle/nanoconjugate concentration. Average background elemental quantity obtained from cell-free nanocomposite-treated blank wells was subtracted from each test sample, to arrive at a final total concentration of nanocomposites taken up by cells. This number was divided by the “end of experiment” cell count to arrive at a Ti concentration per 10<sup>5</sup> cells. Uptake of bare nanocomposites was used as a standard and uptake of nanoconjugates was expressed as a percentage of the Ti concentration found for uncoated nanocomposites.</p></sec><sec id="Sec14"><title>Evaluation of apoptosis/necrosis by flow cytometry</title><p id="Par65">SK-N-AS cells were seeded onto 6-well plates (2 × 10<sup>5</sup> cells per well) and allowed to attach overnight. Cells treated with 250 nM DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites for one hour as well as untreated controls were either sham irradiated or exposed to 10 Gy of gamma rays from a <sup>137</sup>Cs irradiator. Cells were then incubated for 24 h, washed with PBS, trypsinized and processed according to manufacturer’s instructions. 10<sup>5</sup> cells in 100 μL of Annexin-binding buffer were incubated with Annexin-FITC and propidium iodide (PI) for 15 min at room temperature, placed on ice, and immediately evaluated by flow cytometry using a BD LSR Fortessa Analyzer (BD Biosciences, Franklin Lakes, NJ) at the Robert H. Lurie Comprehensive Cancer Center Flow Cytometry Core Facility at Northwestern University. For each biological replicate, 5000 gated events were analyzed.</p></sec><sec id="Sec15"><title>Evaluation of 53BP1 foci</title><p id="Par66">A total of 200,000 SK-N-AS cells were seeded onto barrier slides and allowed to attach overnight. Cells in 1 ml full medium were then treated with varying concentrations of DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanoconjugates or bare nanocomposites for 1 h. Cells were then irradiated with 2 Gy and incubated for 4 h. Slides were washed with PBS and cells fixed in 3.6% formaldehyde for 10 min at room temperature. Cells were then permeabilized with PBS–Triton (0.2%) for 10 min, rinsed three times with PBS–BSA (1%)—Tween (0.5%) and processed further in the same buffer. Slides were incubated for 1 h with primary antibody against 53BP1 (ab21083—Abcam, Cambridge, UK) used at 1:200 dilution, washed and incubated for 45 min with fluorescent secondary antibody (Alexa Fluor 488—Goat Anti-Rabbit, ab150077, Abcam, Cambridge UK). Nuclei were counterstained with propidium iodide (2.5 μg/ml). Cells were imaged at 40 × magnification with a full field fluorescent Zeiss microscope equipped with a CoolSNAP EZ CCD camera (Photometrics, Tucson AZ, US).</p><p id="Par67">Four experiments were performed with two replicate slides for each treatment condition conducted. The 53BP3 foci in each replicate were counted by a different researcher. Multiple images of each slide were taken, and foci present in at least 100 cells were counted for each treatment group. All experiments were pooled as indicated (slide numbers ranged between 3 and 7) and statistics generated from the pooled data.</p></sec><sec id="Sec16"><title>Cryogenic X-ray fluorescence microscopy (Cryo-XFM)</title><p id="Par68">SK-N-AS and SK-N-DZ cells were seeded on 1.5 mm × 1.5 mm Si<sub>3</sub>N<sub>4</sub> windows overnight (Silson, UK), then treated either with 4.24 µM MIBG (with a resultant 0.05% DMSO concentration), 25.44 µM MIBG (final 0.30% DMSO), 60 µM MIBG (final 2% DMSO), or DMSO control (0.30% DMSO) in 50 µL of full media for 90 min. In nanocomposite treatment experiments, cells were treated with MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>–B-loop nanoconjugates (carrying an equivalent of 60 µM of MIBG) for 90 min in serum-free DMEM. In addition, another set of cells grown on Si<sub>3</sub>N<sub>4</sub> windows were exposed to 250 nM MIBG–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>, 250 nM DOPAC–Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>, or 250 nM of bare (phosphate covered) Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> nanocomposites for 60 min in 50 µL of full media. The windows were washed twice in a Tris glucose buffer (261 mM glucose, 9 mM acetic acid, 10 mM Tris buffer, pH 7.4) and plunge-frozen in liquid ethane using a FEI Vitrobot Mark IV. Frozen hydrated cells were imaged with visible light on a Nikon microscope equipped with an Instec CLM77KCryo-LM stage in order to evaluate the quality of each sample with regard to ice accumulation as well as cell density and distribution.</p><p id="Par69">X-ray fluorescence imaging was done with several different instruments under different conditions. A beam spot size of about 300 or 600 nm was used at the sector 2-ID-D at APS at ANL in combination with a cryo-jet; while the Bionanoprobe at sector 21 LS-CAT was used with a beam spot size 85 nm, and the samples were maintained in vacuum at liquid nitrogen temperature. High-resolution elemental maps were obtained at different angles, allowing subsequent tomographic reconstruction. A monochromatic 10 keV X-ray beam was used and the cells were scanned in “continuous” (fly-scan) mode. Step scans for an area of interest were also done at a step size of 80 nm and per-pixel dwell time of 3 s. To minimize background noise, a Gaussian smoothing filter (<italic>σ</italic> = 2/3) was applied to the images in the figures presented.</p><p id="Par70">For tomographic reconstruction, scans were done at multiple angles (3-degree increments, total angular range of 138 degrees); reconstructions were performed in Mathematica 9.0 (Wolfram Research, Champaign, IL). In order to circumvent misalignment of particles as a result of sample movement during scanning, the “displacement” of particles with clear projections (Cl, I, K, P and S) was analyzed, and the average shift along the x and y axis of these particles was calculated. Correction of any displacement of the tested particles was achieved by applying this calculated shift to all the particles, hence any misalignment was adjusted. Tomographic reconstruction was attained by implementing a modified simultaneous iterative reconstruction technique (SIRT) rather than filtered back projection (FBP) since the later yields poor images owing to the limited number of projections. Use of SIRT was described previously with the final visualization of elemental signals of interest using Avizo (FEI, Burlington, MA) (Vo et al. <xref ref-type="bibr" rid="CR65">2014</xref>). Elemental concentration data were extracted for each pixel of the 2D images (elemental quantification, per-pixel fitting) using the MAPS program (Vogt et al. <xref ref-type="bibr" rid="CR66">2003</xref>).</p></sec><sec id="Sec17"><title>Statistical analyses</title><p id="Par71">All comparisons were performed using Student’s <italic>T</italic>-test at a significance level of 0.05. Data points in all figures correspond to mean ± standard deviation.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>Cryo EDS-STEM was performed by Charlene Wilke at Northwestern University’s Atomic and Nanoscale Characterization Experimental Center (NUANCE). ICP-MS was performed with help from Keith MacRenaris at Northwestern University’s Quantitative Bioelemental Imaging Center (QBIC). We also thank Dr Tanja Dučić for her help with the infrared spectra interpretation for Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S2.</p></ack><sec sec-type="author-contribution"><title>Authors' contributions</title><p>WL and SM conceived and conducted experiments and conducted data analysis; YY, JD, SC, BLKS, RS, JS and QJ conducted experiments; RB contributed to experimental design; NV conducted data analysis; RB, CR, SG and SR participated in manuscript preparation; SV and CH contributed to data analysis; TP contributed to project design, conducted experiments and contributed to manuscript preparation; CJ and JK contributed to project conception, and GEW contributed to project conception, design and manuscript preparation. All authors read and approved the final manuscript.</p></sec><sec><title>Funding</title><p>This work was supported by the NIH grants CA107467, EB002100, GM104530 and U54 CA151880 and U54CA119341 and a generous gift from Make Your Mark Foundation (<ext-link xlink:href="http://makeyourmark7.org/" ext-link-type="uri">http://makeyourmark7.org/</ext-link>). WL was supported in part by the Northwestern University Biotechnology Cluster Training Grant. XFM was performed at the Advanced Photon Source at Argonne National Laboratory at XOR beamlines 2-ID-D, 2-ID-E, and LS-CAT 21-ID-D Bionanoprobe; this instrument was obtained through an NIH ARRA S10 grant SP0007167. Work at Argonne National Laboratory was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, Contract No. DE-AC02-06CH11357. We also thank Argonne National Laboratory for support under LDRD project 2013-168-N0.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analyzed during this study are included in this published article and its Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref> and Additional file <xref ref-type="supplementary-material" rid="MOESM2">2</xref>.</p></sec><sec sec-type="ethics-statement"><title>Declarations</title><sec id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par72">Not applicable.</p></sec><sec id="FPar2"><title>Consent for publication</title><p id="Par73">I, the corresponding author, Gayle E Woloschak give consent for publication of this manuscript on behalf of all authors.</p><p id="Par74"><inline-graphic xlink:href="MediaObjects/12645_2021_81_Figb_HTML.gif"/></p></sec><sec id="FPar3" sec-type="COI-statement"><title>Competing interests</title><p id="Par75">The authors have no competing interests to declare.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfei</surname><given-names>S</given-names></name><name><surname>Marengo</surname><given-names>B</given-names></name><name><surname>Zuccari</surname><given-names>G</given-names></name><name><surname>Turrini</surname><given-names>F</given-names></name><name><surname>Domenicotti</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Dendrimer nanodevices and gallic acid as novel strategies to fight chemoresistance in neuroblastoma cells</article-title><source>Nanomaterials</source><year>2020</year><pub-id pub-id-type="doi">10.3390/nano10061243</pub-id></mixed-citation></ref><ref id="CR2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>HC</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>S</given-names></name><name><surname>Paunesku</surname><given-names>T</given-names></name><name><surname>Woloschak</surname><given-names>GE</given-names></name></person-group><article-title xml:lang="en">Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>769</fpage><lpage>778</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38XhslCjtrc%3D</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2890</pub-id></mixed-citation></ref><ref id="CR3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aygun</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">Biological and genetic features of neuroblastoma and their clinical importance</article-title><source>Curr Pediatr Rev</source><year>2018</year><volume>14</volume><fpage>73</fpage><lpage>90</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhs1Omt77P</pub-id><pub-id pub-id-type="doi">10.2174/1573396314666180129101627</pub-id></mixed-citation></ref><ref id="CR4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baade</surname><given-names>PD</given-names></name><name><surname>Youlden</surname><given-names>DR</given-names></name><name><surname>Valery</surname><given-names>PC</given-names></name><name><surname>Hassall</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>AC</given-names></name><name><surname>Aitken</surname><given-names>JF</given-names></name></person-group><article-title xml:lang="en">Trends in incidence of childhood cancer in Australia, 1983–2006</article-title><source>Br J Cancer</source><year>2010</year><volume>102</volume><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DC%2BC3c%2FnsF2ntg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6605503</pub-id></mixed-citation></ref><ref id="CR5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazak</surname><given-names>R</given-names></name><etal/></person-group><article-title xml:lang="en">Cytotoxicity and DNA cleavage with core-shell nanocomposites functionalized by a KH domain DNA binding peptide</article-title><source>Nanoscale</source><year>2013</year><volume>5</volume><fpage>11394</fpage><lpage>11399</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhslCnsb7N</pub-id><pub-id pub-id-type="doi">10.1039/c3nr02203j</pub-id></mixed-citation></ref><ref id="CR6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazak</surname><given-names>R</given-names></name><name><surname>Houri</surname><given-names>M</given-names></name><name><surname>Achy</surname><given-names>SE</given-names></name><name><surname>Hussein</surname><given-names>W</given-names></name><name><surname>Refaat</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Passive targeting of nanoparticles to cancer: a comprehensive review of the literature Mol</article-title><source>Clin Oncol</source><year>2014</year><volume>2</volume><fpage>904</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.3892/mco.2014.356</pub-id></mixed-citation></ref><ref id="CR7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazak</surname><given-names>R</given-names></name><name><surname>Houri</surname><given-names>M</given-names></name><name><surname>El Achy</surname><given-names>S</given-names></name><name><surname>Kamel</surname><given-names>S</given-names></name><name><surname>Refaat</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Cancer active targeting by nanoparticles: a comprehensive review of literature</article-title><source>J Cancer Res Clin Oncol</source><year>2015</year><volume>141</volume><fpage>769</fpage><lpage>784</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhtFentLrO</pub-id><pub-id pub-id-type="doi">10.1007/s00432-014-1767-3</pub-id></mixed-citation></ref><ref id="CR8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blake</surname><given-names>DM</given-names></name><name><surname>Maness</surname><given-names>P-C</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Wolfrum</surname><given-names>EJ</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Jacoby</surname><given-names>WA</given-names></name></person-group><article-title xml:lang="en">Application of the photocatalytic chemistry of titanium dioxide to disinfection and the killing of cancer cells</article-title><source>Sep Purif Methods</source><year>1999</year><volume>28</volume><fpage>1</fpage><lpage>50</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK1MXjsVamsrc%3D</pub-id><pub-id pub-id-type="doi">10.1080/03602549909351643</pub-id></mixed-citation></ref><ref id="CR9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><etal/></person-group><article-title xml:lang="en">Intracellular in situ labeling of TiO(2) nanoparticles for fluorescence microscopy detection</article-title><source>Nano Res</source><year>2018</year><volume>11</volume><fpage>464</fpage><lpage>476</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXht1Gjt7fM</pub-id><pub-id pub-id-type="doi">10.1007/s12274-017-1654-8</pub-id></mixed-citation></ref><ref id="CR10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlin</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>3338</fpage><lpage>3344</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXotFCksb8%3D</pub-id></mixed-citation></ref><ref id="CR11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chagnovich</surname><given-names>D</given-names></name><name><surname>Cohn</surname><given-names>SL</given-names></name></person-group><article-title xml:lang="en">Activity of a 40 kDa RNA-binding protein correlates with MYCN and c-fos mRNA stability in human neuroblastoma</article-title><source>Eur J Cancer</source><year>1997</year><volume>33</volume><fpage>2064</fpage><lpage>2067</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK1cXjt1GnsQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/s0959-8049(97)00208-6</pub-id></mixed-citation></ref><ref id="CR12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">The Bionanoprobe: hard X-ray fluorescence nanoprobe with cryogenic capabilities</article-title><source>J Synchrotron Radiat</source><year>2014</year><volume>21</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXmt1Gnsg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1107/S1600577513029676</pub-id></mixed-citation></ref><ref id="CR13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clerc</surname><given-names>J</given-names></name><name><surname>Halpern</surname><given-names>S</given-names></name><name><surname>Fourre</surname><given-names>C</given-names></name><name><surname>Omri</surname><given-names>F</given-names></name><name><surname>Briancon</surname><given-names>C</given-names></name><name><surname>Jeusset</surname><given-names>J</given-names></name><name><surname>Fragu</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice</article-title><source>J Nucl Med</source><year>1993</year><volume>34</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK2cXht1ylsb4%3D</pub-id></mixed-citation></ref><ref id="CR14"><mixed-citation publication-type="other">Clogston JD (2009) Ncl method pcc-2 measuring zeta potential of nanoparticles. 2020. <ext-link xlink:href="http://ncl.cancer.gov/NCL_Method_PCC-2.pdf" ext-link-type="uri">http://ncl.cancer.gov/NCL_Method_PCC-2.pdf</ext-link>.</mixed-citation></ref><ref id="CR15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>MS</given-names></name><name><surname>Evans</surname><given-names>MD</given-names></name><name><surname>Dizdaroglu</surname><given-names>M</given-names></name><name><surname>Lunec</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Oxidative DNA damage: mechanisms, mutation, and disease</article-title><source>FASEB J</source><year>2003</year><volume>17</volume><fpage>1195</fpage><lpage>1214</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXltFeru78%3D</pub-id><pub-id pub-id-type="doi">10.1096/fj.02-0752rev</pub-id></mixed-citation></ref><ref id="CR16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creutz</surname><given-names>C</given-names></name><name><surname>Chou</surname><given-names>MH</given-names></name></person-group><article-title xml:lang="en">Binding of catechols to mononuclear titanium(IV) and to 1- and 5-nm TiO2 nanoparticles</article-title><source>Inorg Chem</source><year>2008</year><volume>47</volume><fpage>3509</fpage><lpage>3514</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXjvVSiu7o%3D</pub-id><pub-id pub-id-type="doi">10.1021/ic701687k</pub-id></mixed-citation></ref><ref id="CR17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>SH</given-names></name><name><surname>Mairs</surname><given-names>RJ</given-names></name><name><surname>Wheldon</surname><given-names>TE</given-names></name><name><surname>Welsh</surname><given-names>PC</given-names></name><name><surname>Vaidyanathan</surname><given-names>G</given-names></name><name><surname>Zalutsky</surname><given-names>MR</given-names></name></person-group><article-title xml:lang="en">Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>2061</fpage><lpage>2068</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK1cXktlCmt78%3D</pub-id><pub-id pub-id-type="doi">10.1038/bjc.1998.348</pub-id></mixed-citation></ref><ref id="CR18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Paolo</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Combined replenishment of miR-34a and let-7b by targeted nanoparticles inhibits tumor growth in neuroblastoma preclinical models</article-title><source>Small</source><year>2020</year><volume>16</volume><fpage>e1906426</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXnvVemsr8%3D</pub-id><pub-id pub-id-type="doi">10.1002/smll.201906426</pub-id></mixed-citation></ref><ref id="CR19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmann</surname><given-names>K</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Kehlbach</surname><given-names>R</given-names></name><name><surname>Rodemann</surname><given-names>HP</given-names></name></person-group><article-title xml:lang="en">Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK</article-title><source>Mol Cancer</source><year>2008</year><volume>7</volume><fpage>69</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhtlSls77E</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-7-69</pub-id></mixed-citation></ref><ref id="CR20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmann</surname><given-names>K</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Fehrenbacher</surname><given-names>B</given-names></name><name><surname>Schaller</surname><given-names>M</given-names></name><name><surname>Kehlbach</surname><given-names>R</given-names></name><name><surname>Rodemann</surname><given-names>HP</given-names></name></person-group><article-title xml:lang="en">Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654</article-title><source>FEBS Lett</source><year>2010</year><volume>584</volume><fpage>3878</fpage><lpage>3884</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXht1WmurrL</pub-id><pub-id pub-id-type="doi">10.1016/j.febslet.2010.08.005</pub-id></mixed-citation></ref><ref id="CR21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname><given-names>SG</given-names></name><name><surname>Matthay</surname><given-names>KK</given-names></name></person-group><article-title xml:lang="en">Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma</article-title><source>Nucl Med Biol</source><year>2008</year><volume>35</volume><issue>Suppl 1</issue><fpage>S35</fpage><lpage>48</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1cXhtVShtrjK</pub-id><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2008.05.002</pub-id></mixed-citation></ref><ref id="CR22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname><given-names>SG</given-names></name><etal/></person-group><article-title xml:lang="en">Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival</article-title><source>J Pediatr Hematol Oncol</source><year>1999</year><volume>21</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DyaK1M3ptVGiug%3D%3D</pub-id><pub-id pub-id-type="doi">10.1097/00043426-199905000-00005</pub-id></mixed-citation></ref><ref id="CR23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eleveld</surname><given-names>TF</given-names></name><etal/></person-group><article-title xml:lang="en">Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><fpage>864</fpage><lpage>871</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXhtFeju7rL</pub-id><pub-id pub-id-type="doi">10.1038/ng.3333</pub-id></mixed-citation></ref><ref id="CR24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finney</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>2247</fpage><lpage>2252</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2sXisVWrsbs%3D</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0607238104</pub-id></mixed-citation></ref><ref id="CR25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>J</given-names></name><name><surname>Cohn</surname><given-names>SL</given-names></name><name><surname>Salwen</surname><given-names>HR</given-names></name><name><surname>Chagnovich</surname><given-names>D</given-names></name><name><surname>Cowan</surname><given-names>J</given-names></name><name><surname>Mason</surname><given-names>KL</given-names></name><name><surname>Parysek</surname><given-names>LM</given-names></name></person-group><article-title xml:lang="en">Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>6338</fpage><lpage>6345</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK38Xhsl2qug%3D%3D</pub-id></mixed-citation></ref><ref id="CR26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatta</surname><given-names>G</given-names></name><etal/></person-group><article-title xml:lang="en">Embryonal cancers in Europe</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>1425</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.12.027</pub-id></mixed-citation></ref><ref id="CR27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaze</surname><given-names>MN</given-names></name><name><surname>Huxham</surname><given-names>IM</given-names></name><name><surname>Mairs</surname><given-names>RJ</given-names></name><name><surname>Barrett</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging</article-title><source>Int J Cancer</source><year>1991</year><volume>47</volume><fpage>875</fpage><lpage>880</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DyaK3M7osV2jtw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1002/ijc.2910470615</pub-id></mixed-citation></ref><ref id="CR28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glesne</surname><given-names>D</given-names></name><name><surname>Vogt</surname><given-names>S</given-names></name><name><surname>Maser</surname><given-names>J</given-names></name><name><surname>Legnini</surname><given-names>D</given-names></name><name><surname>Huberman</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Regulatory properties and cellular redistribution of zinc during macrophage differentiation of human leukemia cells</article-title><source>J Struct Biol</source><year>2006</year><volume>155</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD28XlvF2nsLs%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.jsb.2005.09.012</pub-id></mixed-citation></ref><ref id="CR29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glowniak</surname><given-names>JV</given-names></name><name><surname>Kilty</surname><given-names>JE</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name><name><surname>Hoffman</surname><given-names>BJ</given-names></name><name><surname>Turner</surname><given-names>FE</given-names></name></person-group><article-title xml:lang="en">Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters</article-title><source>J Nucl Med</source><year>1993</year><volume>34</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK2cXht1CjtLg%3D</pub-id></mixed-citation></ref><ref id="CR30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grätzel</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Conversion of sunlight to electric power by nanocrystalline dye-sensitized solar cells</article-title><source>J Photochem Photobiol A Chem</source><year>2004</year><volume>164</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2cXktFKqtbY%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.jphotochem.2004.02.023</pub-id></mixed-citation></ref><ref id="CR31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>R</given-names></name><etal/></person-group><article-title xml:lang="en">Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>9868</fpage><lpage>9875</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2MXhtFKktLrN</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2426</pub-id></mixed-citation></ref><ref id="CR32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>WA</given-names></name></person-group><article-title xml:lang="en">Neuroblastoma and MYCN</article-title><source>Cold Spring Harb Perspect Med</source><year>2013</year><volume>3</volume><fpage>a014415</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhvFeisbvP</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a014415</pub-id></mixed-citation></ref><ref id="CR33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iavarone</surname><given-names>A</given-names></name><name><surname>Lasorella</surname><given-names>A</given-names></name><name><surname>Servidei</surname><given-names>T</given-names></name><name><surname>Riccardi</surname><given-names>R</given-names></name><name><surname>Mastrangelo</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK3sXhtFKgsL4%3D</pub-id></mixed-citation></ref><ref id="CR34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kacar</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Solid tumors in Turkish children: a multicenter study</article-title><source>World J Pediatr</source><year>2013</year><volume>9</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s12519-011-0323-3</pub-id></mixed-citation></ref><ref id="CR35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karmakar</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>KA</given-names></name><name><surname>Choudhury</surname><given-names>SR</given-names></name><name><surname>Deeconda</surname><given-names>A</given-names></name><name><surname>Banik</surname><given-names>NL</given-names></name><name><surname>Ray</surname><given-names>SK</given-names></name></person-group><article-title xml:lang="en">Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>388</volume><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1MXhtFajsb%2FL</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.08.071</pub-id></mixed-citation></ref><ref id="CR36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayano</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">High-dose (131)I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan</article-title><source>Ann Nucl Med</source><year>2020</year><volume>34</volume><fpage>397</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s12149-020-01460-z</pub-id></mixed-citation></ref><ref id="CR37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>van Golen</surname><given-names>CM</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group><article-title xml:lang="en">Insulin-like growth factor-I signaling in human neuroblastoma cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>130</fpage><lpage>141</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2cXovVKiuw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206924</pub-id></mixed-citation></ref><ref id="CR38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SY</given-names></name><etal/></person-group><article-title xml:lang="en">Nuclear localization of EGF receptor and its potential new role as a transcription factor</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><fpage>802</fpage><lpage>808</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3MXmvF2ls74%3D</pub-id><pub-id pub-id-type="doi">10.1038/ncb0901-802</pub-id></mixed-citation></ref><ref id="CR39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>HW</given-names></name><name><surname>Ali-Seyed</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Bartholomeusz</surname><given-names>G</given-names></name><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name></person-group><article-title xml:lang="en">Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1</article-title><source>J Cell Biochem</source><year>2006</year><volume>98</volume><fpage>1570</fpage><lpage>1583</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD28XnvFWku7o%3D</pub-id><pub-id pub-id-type="doi">10.1002/jcb.20876</pub-id></mixed-citation></ref><ref id="CR40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>JM</given-names></name></person-group><article-title xml:lang="en">Recent advances in neuroblastoma</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>2202</fpage><lpage>2211</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXnsV2htr0%3D</pub-id><pub-id pub-id-type="doi">10.1056/NEJMra0804577</pub-id></mixed-citation></ref><ref id="CR41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>JM</given-names></name><name><surname>Hogarty</surname><given-names>MD</given-names></name><name><surname>Bagatell</surname><given-names>R</given-names></name><name><surname>Cohn</surname><given-names>SL</given-names></name></person-group><article-title xml:lang="en">Neuroblastoma</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>2106</fpage><lpage>2120</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2sXmvVKqtb0%3D</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60983-0</pub-id></mixed-citation></ref><ref id="CR42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthay</surname><given-names>KK</given-names></name><etal/></person-group><article-title xml:lang="en">Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1054</fpage><lpage>1060</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2sXksVyrs7w%3D</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2006.09.3484</pub-id></mixed-citation></ref><ref id="CR43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthay</surname><given-names>KK</given-names></name><name><surname>George</surname><given-names>RE</given-names></name><name><surname>Yu</surname><given-names>AL</given-names></name></person-group><article-title xml:lang="en">Promising therapeutic targets in neuroblastoma</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>2740</fpage><lpage>2753</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38Xnt1Cjs7k%3D</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1939</pub-id></mixed-citation></ref><ref id="CR44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelmore</surname><given-names>A</given-names></name><name><surname>Gong</surname><given-names>WQ</given-names></name><name><surname>Jenkins</surname><given-names>P</given-names></name><name><surname>Ralston</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">The interaction of linear polyphosphates with titanium dioxide surfaces PCCP</article-title><source>Phys Chem Chem Phys</source><year>2000</year><volume>2</volume><fpage>2985</fpage><lpage>2992</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3cXktlCntL8%3D</pub-id><pub-id pub-id-type="doi">10.1039/b001213k</pub-id></mixed-citation></ref><ref id="CR45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>R</given-names></name><name><surname>Sahoo</surname><given-names>SK</given-names></name></person-group><article-title xml:lang="en">Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy</article-title><source>Eur J Pharm Sci</source><year>2010</year><volume>39</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXotVyntQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.ejps.2009.11.010</pub-id></mixed-citation></ref><ref id="CR46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawara</surname><given-names>A</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Tasaka</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Dopaminergic neuroblastoma as a poor prognostic subgroup</article-title><source>J Pediatr Surg</source><year>1988</year><volume>23</volume><fpage>346</fpage><lpage>349</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DyaL1c3lvVOqsw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/s0022-3468(88)80204-5</pub-id></mixed-citation></ref><ref id="CR47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Ozaki</surname><given-names>T</given-names></name><name><surname>Niizuma</surname><given-names>H</given-names></name><name><surname>Ohira</surname><given-names>M</given-names></name><name><surname>Kamijo</surname><given-names>T</given-names></name><name><surname>Nakagawara</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line</article-title><source>Biochem Biophys Res Commun</source><year>2007</year><volume>354</volume><fpage>892</fpage><lpage>898</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2sXhs1Sntr0%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.01.057</pub-id></mixed-citation></ref><ref id="CR48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakatani</surname><given-names>T</given-names></name><name><surname>Hayama</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Takemoto</surname><given-names>Y</given-names></name><name><surname>Sugimura</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging</article-title><source>Oncol Rep</source><year>2002</year><volume>9</volume><fpage>1225</fpage><lpage>1227</lpage></mixed-citation></ref><ref id="CR49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>R</given-names></name><name><surname>Bohic</surname><given-names>S</given-names></name><name><surname>Tucoulou</surname><given-names>R</given-names></name><name><surname>Somogyi</surname><given-names>A</given-names></name><name><surname>Deves</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Microchemical element imaging of yeast and human cells using synchrotron X-ray microprobe with Kirkpatrick-Baez optics</article-title><source>Anal Chem</source><year>2004</year><volume>76</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXpsFaqs70%3D</pub-id><pub-id pub-id-type="doi">10.1021/ac035037r</pub-id></mixed-citation></ref><ref id="CR50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paltiel</surname><given-names>HJ</given-names></name><name><surname>Gelfand</surname><given-names>MJ</given-names></name><name><surname>Elgazzar</surname><given-names>AH</given-names></name><name><surname>Washburn</surname><given-names>LC</given-names></name><name><surname>Harris</surname><given-names>RE</given-names></name><name><surname>Masters</surname><given-names>PR</given-names></name><name><surname>Golsch</surname><given-names>GJ</given-names></name></person-group><article-title xml:lang="en">Neural crest tumors: I-123 MIBG imaging in children</article-title><source>Radiology</source><year>1994</year><volume>190</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DyaK2c%2Fot1WmsQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1148/radiology.190.1.8259387</pub-id></mixed-citation></ref><ref id="CR51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pante</surname><given-names>N</given-names></name><name><surname>Kann</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm</article-title><source>Mol Biol Cell</source><year>2002</year><volume>13</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD38XivVertrg%3D</pub-id><pub-id pub-id-type="doi">10.1091/mbc.01-06-0308</pub-id></mixed-citation></ref><ref id="CR52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulo</surname><given-names>CS</given-names></name><name><surname>das Pires Neves</surname><given-names>R</given-names></name><name><surname>Ferreira</surname><given-names>LS</given-names></name></person-group><article-title xml:lang="en">Nanoparticles for intracellular-targeted drug delivery</article-title><source>Nanotechnology</source><year>2011</year><volume>22</volume><fpage>494002</fpage><pub-id pub-id-type="doi">10.1088/0957-4484/22/49/494002</pub-id></mixed-citation></ref><ref id="CR53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paunesku</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Biology of TiO2-oligonucleotide nanocomposites</article-title><source>Nat Mater</source><year>2003</year><volume>2</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXjtlaltbY%3D</pub-id><pub-id pub-id-type="doi">10.1038/nmat875</pub-id></mixed-citation></ref><ref id="CR54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paunesku</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Intracellular distribution of TiO2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity</article-title><source>Nano Lett</source><year>2007</year><volume>7</volume><fpage>596</fpage><lpage>601</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2sXht1Wqs7w%3D</pub-id><pub-id pub-id-type="doi">10.1021/nl0624723</pub-id></mixed-citation></ref><ref id="CR55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajh</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>LX</given-names></name><name><surname>Lukas</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Thurnauer</surname><given-names>MC</given-names></name><name><surname>Tiede</surname><given-names>DM</given-names></name></person-group><article-title xml:lang="en">Surface restructuring of nanoparticles: an efficient route for ligand−metal oxide crosstalk</article-title><source>J Phys Chem B</source><year>2002</year><volume>106</volume><fpage>10543</fpage><lpage>10552</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD38XmvFWlu70%3D</pub-id><pub-id pub-id-type="doi">10.1021/jp021235v</pub-id></mixed-citation></ref><ref id="CR56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutgers</surname><given-names>M</given-names></name><name><surname>Buitenhuis</surname><given-names>CK</given-names></name><name><surname>van der Valk</surname><given-names>MA</given-names></name><name><surname>Hoefnagel</surname><given-names>CA</given-names></name><name><surname>Voûte</surname><given-names>PA</given-names></name><name><surname>Smets</surname><given-names>LA</given-names></name></person-group><article-title xml:lang="en">[(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts</article-title><source>Int J Cancer</source><year>2000</year><volume>90</volume><fpage>312</fpage><lpage>325</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3MXltFOmsg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1002/1097-0215(20001220)90:6&lt;312::AID-IJC2&gt;3.0.CO;2-Z</pub-id></mixed-citation></ref><ref id="CR57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryter</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>HP</given-names></name><name><surname>Hoetzel</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Nakahira</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Choi</surname><given-names>AM</given-names></name></person-group><article-title xml:lang="en">Mechanisms of cell death in oxidative stress</article-title><source>Antioxid Redox Signal</source><year>2007</year><volume>9</volume><fpage>49</fpage><lpage>89</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD28Xht1Wqur3L</pub-id><pub-id pub-id-type="doi">10.1089/ars.2007.9.49</pub-id></mixed-citation></ref><ref id="CR58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schramm</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Mutational dynamics between primary and relapse neuroblastomas</article-title><source>Nat Genet</source><year>2015</year><volume>47</volume><fpage>872</fpage><lpage>877</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXhtFeju7vP</pub-id><pub-id pub-id-type="doi">10.1038/ng.3349</pub-id></mixed-citation></ref><ref id="CR59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisson</surname><given-names>JC</given-names></name><etal/></person-group><article-title xml:lang="en">Iodine-125-MIBG to treat neuroblastoma: preliminary report</article-title><source>J Nucl Med</source><year>1990</year><volume>31</volume><fpage>1479</fpage><lpage>1485</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:STN:280:DyaK3czmvFensA%3D%3D</pub-id></mixed-citation></ref><ref id="CR60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>CA</given-names></name></person-group><article-title xml:lang="en">Epidemiology and genetics of childhood cancer</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>6429</fpage><lpage>6444</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2cXmvVOrtLg%3D</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207717</pub-id></mixed-citation></ref><ref id="CR61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>M</given-names></name><name><surname>Seigo</surname><given-names>K</given-names></name><name><surname>Hosoya</surname><given-names>Y</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Manabe</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">(131) I-MIBG therapy with WT-1 peptide for refractory neuroblastoma</article-title><source>Pediatr Int</source><year>2020</year><volume>62</volume><fpage>746</fpage><lpage>747</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXht1yjtr7L</pub-id><pub-id pub-id-type="doi">10.1111/ped.14175</pub-id></mixed-citation></ref><ref id="CR62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurn</surname><given-names>KT</given-names></name><etal/></person-group><article-title xml:lang="en">Labeling TiO2 nanoparticles with dyes for optical fluorescence microscopy and determination of TiO2-DNA nanoconjugate stability</article-title><source>Small</source><year>2009</year><volume>5</volume><fpage>1318</fpage><lpage>1325</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD1MXnslCksLc%3D</pub-id><pub-id pub-id-type="doi">10.1002/smll.200801458</pub-id></mixed-citation></ref><ref id="CR63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurn</surname><given-names>KT</given-names></name><etal/></person-group><article-title xml:lang="en">Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells</article-title><source>Nanomedicine</source><year>2011</year><volume>7</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXltFGjs7s%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.nano.2010.09.004</pub-id></mixed-citation></ref><ref id="CR64"><mixed-citation publication-type="other">Tubiana M (2005) Introduction to radiobiology. CRC Press. <ext-link xlink:href="http://books.google.com/books?id=xiuNc-2H9UEC" ext-link-type="uri">http://books.google.com/books?id=xiuNc-2H9UEC</ext-link>. Accessed Dec 2016.</mixed-citation></ref><ref id="CR65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vo</surname><given-names>NT</given-names></name><name><surname>Drakopoulos</surname><given-names>M</given-names></name><name><surname>Atwood</surname><given-names>RC</given-names></name><name><surname>Reinhard</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Reliable method for calculating the center of rotation in parallel-beam tomography</article-title><source>Opt Express</source><year>2014</year><volume>22</volume><fpage>19078</fpage><lpage>19086</lpage><pub-id pub-id-type="doi">10.1364/oe.22.019078</pub-id></mixed-citation></ref><ref id="CR66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>S</given-names></name><name><surname>Maser</surname><given-names>J</given-names></name><name><surname>Jacobsen</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Data analysis for x-ray fluorescence imaging</article-title><source>J De Phys IV</source><year>2003</year><volume>104</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD3sXksVansLo%3D</pub-id><pub-id pub-id-type="doi">10.1051/jp4:20030156</pub-id></mixed-citation></ref><ref id="CR67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YN</given-names></name><etal/></person-group><article-title xml:lang="en">The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>38720</fpage><lpage>38729</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXhsVOku7nK</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M110.158659</pub-id></mixed-citation></ref><ref id="CR68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>HH</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name></person-group><article-title xml:lang="en">COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport</article-title><source>Biochem Biophys Res Commun</source><year>2010</year><volume>399</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXhtFamsLjK</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.07.096</pub-id></mixed-citation></ref><ref id="CR69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>DeSantis</surname><given-names>C</given-names></name><name><surname>Robbins</surname><given-names>A</given-names></name><name><surname>Kohler</surname><given-names>B</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Childhood and adolescent cancer statistics</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>83</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.3322/caac.21219</pub-id></mixed-citation></ref><ref id="CR70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>W</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Senekowitsch-Schmidtke</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>5428</fpage><lpage>5434</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DyaK28Xntl2mtLw%3D</pub-id></mixed-citation></ref><ref id="CR71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>GJ</given-names></name></person-group><article-title xml:lang="en">Emerging roles of Myc in stem cell biology and novel tumor therapies</article-title><source>J Exp Clin Cancer Res</source><year>2018</year><volume>37</volume><fpage>173</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXivVemtrk%3D</pub-id><pub-id pub-id-type="doi">10.1186/s13046-018-0835-y</pub-id></mixed-citation></ref><ref id="CR72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><etal/></person-group><article-title xml:lang="en">Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells</article-title><source>ACS Nano</source><year>2013</year><volume>7</volume><fpage>10502</fpage><lpage>10517</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXhslOms7%2FJ</pub-id><pub-id pub-id-type="doi">10.1021/nn4033294</pub-id></mixed-citation></ref><ref id="CR73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zage</surname><given-names>PE</given-names></name><etal/></person-group><article-title xml:lang="en">UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>915</fpage><lpage>923</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXitVOhsrc%3D</pub-id><pub-id pub-id-type="doi">10.1002/cncr.27785</pub-id></mixed-citation></ref><ref id="CR74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorov</surname><given-names>DB</given-names></name><name><surname>Juhaszova</surname><given-names>M</given-names></name><name><surname>Sollott</surname><given-names>SJ</given-names></name></person-group><article-title xml:lang="en">Mitochondrial ROS-induced ROS release: an update and review</article-title><source>Biochim Biophys Acta</source><year>2006</year><volume>1757</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD28Xmsl2jtrc%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.bbabio.2006.04.029</pub-id></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1" specific-use="web-only"><sec id="Sec18"><title>Supplementary Information</title><p id="Par76"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary Information"><media mimetype="application" mime-subtype="msword" xlink:href="MediaObjects/12645_2021_81_MOESM1_ESM.docx" position="anchor"><caption xml:lang="en"><p><bold>Additional file 1.</bold> Additional tables and figures.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary Information"><media mimetype="video" mime-subtype="mp4" xlink:href="MediaObjects/12645_2021_81_MOESM2_ESM.mp4" position="anchor"><caption xml:lang="en"><p><bold>Additional file 2.</bold> Video of the rotation of the cell shown in Figure 3.</p></caption></media></supplementary-material></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>53BP1</term><def><p id="Par200">P53-Binding Protein 1</p></def></def-item><def-item><term>AFM</term><def><p id="Par4">Atomic force microscopy</p></def></def-item><def-item><term>APS</term><def><p id="Par5">Advanced Photon Source</p></def></def-item><def-item><term>ANL</term><def><p id="Par6">Argonne National Laboratory</p></def></def-item><def-item><term>DNA</term><def><p id="Par7">Deoxyribonucleic acid</p></def></def-item><def-item><term>DOPAC</term><def><p id="Par8">3,4-Dihydroxyphenylacetic acid</p></def></def-item><def-item><term>EDS</term><def><p id="Par9">Energy-dispersive X-ray spectroscopy</p></def></def-item><def-item><term>EDC</term><def><p id="Par10">1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride</p></def></def-item><def-item><term>EGF</term><def><p id="Par11">Epidermal growth factor</p></def></def-item><def-item><term>EGFR</term><def><p id="Par12">Epidermal growth factor receptor</p></def></def-item><def-item><term>Fe<sub>3</sub>O<sub>4</sub></term><def><p id="Par13">Iron oxide</p></def></def-item><def-item><term>Fe<sub>3</sub>O<sub>4</sub> @ TiO<sub>2</sub></term><def><p id="Par14">Iron oxide core, titanium dioxide shell nanocomposite</p></def></def-item><def-item><term>ICP-MS</term><def><p id="Par15">Inductively coupled plasma-mass spectrometry</p></def></def-item><def-item><term>IRENI</term><def><p id="Par16">Infrared environmental imaging</p></def></def-item><def-item><term>MIBG</term><def><p id="Par17">Metaiodobenzylguanidine</p></def></def-item><def-item><term>MTS</term><def><p id="Par18">3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium</p></def></def-item><def-item><term>MYCN</term><def><p id="Par19">N-myc proto-oncogene protein</p></def></def-item><def-item><term>NRER</term><def><p id="Par20">Nanocomposite radiation enhancement ratio</p></def></def-item><def-item><term>TEM</term><def><p id="Par21">Transmission electron microscope</p></def></def-item><def-item><term>TiO<sub>2</sub></term><def><p id="Par22">Titanium dioxide</p></def></def-item><def-item><term>S-type</term><def><p id="Par23">Epithelial morphology in neuroblastoma</p></def></def-item><def-item><term>SER</term><def><p id="Par24">Sensitizer enhancement ratio</p></def></def-item><def-item><term>STEM</term><def><p id="Par25">Scanning transmission electron microscope</p></def></def-item><def-item><term>RAS–MAPK</term><def><p id="Par26">RAS–mitogen-activated protein kinase</p></def></def-item><def-item><term>ROI</term><def><p id="Par27">Region of interest</p></def></def-item><def-item><term>XFM</term><def><p id="Par28">X-ray fluorescence microscopy</p></def></def-item></def-list></glossary><notes notes-type="Misc"><title>Publisher's Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Biochemistry, general</facet-value><facet-value count="1">Biomedical Engineering and Bioengineering</facet-value><facet-value count="1">Cancer Research</facet-value><facet-value count="1">Materials Science</facet-value><facet-value count="1">Nanotechnology</facet-value></facet><facet name="keyword"><facet-value count="1">Iron oxide core nanoparticles</facet-value><facet-value count="1">Nanocomposites</facet-value><facet-value count="1">Nanoconjugates</facet-value><facet-value count="1">Neuroblastoma</facet-value><facet-value count="1">Radiosensitization</facet-value><facet-value count="1">Titanium dioxide shell nanoparticles</facet-value></facet><facet name="pub"><facet-value count="1">Cancer Nanotechnology</facet-value></facet><facet name="year"><facet-value count="1">2021</facet-value></facet><facet name="country"><facet-value count="1">Egypt</facet-value><facet-value count="1">United Kingdom</facet-value><facet-value count="1">United States</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
